aspirin has been researched along with Fetal Growth Retardation in 188 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Fetal Growth Retardation: Failure of a FETUS to attain expected GROWTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the impact of low-dose aspirin (LDA) starting in early pregnancy on delaying preterm hypertensive disorders of pregnancy." | 9.69 | Aspirin delays the onset of hypertensive disorders of pregnancy among nulliparous pregnant women: A secondary analysis of the ASPIRIN trial. ( Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Koso-Thomas, M; Krebs, NF; Lokangaka, A; McClure, EM; Metgud, MC; Moore, J; Mwenechanya, M; Nielsen, E; Patel, A; Saleem, S; Silver, R; Somannavar, MS; Tshefu, A, 2023) |
| " The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage." | 9.41 | Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023) |
| "To establish the clinical heterogeneity among the clinical practice guidelines (CPGs) on aspirin use in pregnancy and to investigate the quality of these CPGs." | 9.41 | Clinical practice guidelines on the use of aspirin in pregnancy: Systematic review. ( Alameddine, S; D'Antonio, F; Di Girolamo, R; Khalil, A; Liberati, M; Maruotti, GM; Rizzo, G; Santilli, F, 2023) |
| " The subjects of the study were randomly assigned into two groups of intervention and control to receive either 80 mg of aspirin or placebo daily during the pregnancy." | 9.34 | The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia. ( Abdi, N; Alavi, A; Asadi, N; Hessami, K; Kasraeian, M; Rozrokh, A; Vafaei, H; Zare, S, 2020) |
| "We observed no significant difference in UtA-PI between the two doses of aspirin, but we observed low rates of fetal growth restriction and preterm and early-onset preeclampsia (all less than 5%)." | 9.34 | A Pilot Randomized Trial Comparing the Effects of 80 versus 160 mg of Aspirin on Midtrimester Uterine Artery Pulsatility Index in Women with a History of Preeclampsia. ( Bujold, E; Côté, S; Ferreira, E; Girard, M; Guerby, P; Leclair, G; Roberge, S; Tapp, S, 2020) |
| "We propose a three armed multi-center open-labeled randomized control trial of; (i) routine LDA, (ii) no aspirin, and (iii) LDA on the basis of a positive first trimester pre-eclampsia screening test." | 9.22 | An open-label randomized-controlled trial of low dose aspirin with an early screening test for pre-eclampsia and growth restriction (TEST): Trial protocol. ( Breathnach, F; Culliton, M; Dicker, P; Downey, P; Malone, FD; McAuliffe, FM; McCormack, D; McParland, P; Mone, F; Mulcahy, C; Stanton, A; Tully, E, 2016) |
| " We included randomized controlled trials reporting on health-related outcomes in children (aged > 28 days) exposed to aspirin versus placebo or no treatment during pregnancy." | 9.12 | Long-term health and neurodevelopment in children after antenatal exposure to low-dose aspirin for the prevention of preeclampsia and fetal growth restriction: A systematic review of randomized controlled trials. ( de Boer, MA; Finken, MJJ; Ket, JCF; Landman, AJEMC; Leemhuis, AG; Oudijk, MA; Painter, RC; van 't Hooft, J; van Limburg Stirum, EVJ, 2021) |
| "The use of low dose aspirin (LDA) has become routine in prenatal care for a variety of diagnoses, most importantly in women with a history of preeclampsia and associated poor pregnancy outcomes." | 9.12 | Low-dose aspirin in pregnancy: who? when? how much? and why? ( Dom, AM; Mather, AR; Thorburg, LL, 2021) |
| " Since low doses of aspirin could improve the utero-placental circulation (by shifting the prostacyclin/thromboxane A2 balance), we have evaluated the impact of low-dose aspirin treatment of IUGR during pregnancy on umbilical (UA) and middle cerebral artery (MCA) blood flow." | 9.11 | [The impact of low-dose aspirin therapy on umbilical and middle cerebral artery blood flow in pregnancy complicated by idiopathic intrauterine growth restriction]. ( Gottwald, L; Kalinka, J; Laudański, T; Lech, W; Nowakowski, M; Zdziennicki, A, 2004) |
| "To investigate the effect of low-dose, slow-release aspirin in reducing the incidence and/or severity of pregnancy complications in women identified as high risk of developing problems associated with uteroplacental insufficiency, namely pre-eclampsia or delivering a small-for-gestational age (SGA) baby." | 9.09 | A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. ( Aquilina, J; Campbell, S; England, P; Harrington, K; Kurdi, W, 2000) |
| "Daily administration of low-dose aspirin during the second and third trimesters of pregnancy does not alter uteroplacental or fetoplacental hemodynamics and does not cause moderate or severe constriction of the ductus arteriosus." | 9.09 | Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. ( Erdmann, M; Grab, D; Kreienberg, R; Lang, D; Muche, R; Oberhoffer, R; Paulus, WE; Terinde, R, 2000) |
| "To determine any benefits or risks, expressed in early childhood, of low dose aspirin treatment in pregnancies at high risk of complications due to pre-eclampsia or intrauterine growth retardation." | 9.08 | Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. ( , 1995) |
| "To determine the effectiveness of low dose aspirin in women at high risk of adverse outcomes associated with pre-eclampsia." | 9.08 | ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. ( , 1996) |
| "The purpose of this study was to investigate the hypothesis that maternal administration of 100mg aspirin each day will improve birth-weight and other measures of neonatal size when given as a treatment to pregnancies complicated by fetal growth restriction and umbilical-placental insufficiency." | 9.08 | Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. ( Evans, SF; Godfrey, M; Newnham, JP; Phillips, J; Walters, BJ, 1995) |
| "The use of low-dose aspirin for the prevention and treatment of pre-eclampsia and intrauterine growth restriction has been studied extensively during the last 10 years." | 9.08 | Effect on fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia and intrauterine growth restriction: Doppler flow study. ( Bar, J; Fisch, B; Hod, M; Kaplan, B; Meizner, I; Pardo, J; Rabinerson, D, 1997) |
| "To investigate whether low dose aspirin medication given to primiparous women provides benefit in preventing pre-eclampsia or intrauterine growth retardation." | 9.08 | A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. ( Golding, J, 1998) |
| "Meta-analysis of data from several controlled trials has shown that low-dose aspirin reduces the risk of pregnancy-induced hypertension (PIH) and intrauterine growth retardation (IUGR) in women at high risk of these disorders." | 9.07 | Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. ( , 1993) |
| "The efficacy of low-dose aspirin in preventing fetal growth retardation was tested in a randomised, placebo-controlled, double-blind trial." | 9.07 | Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. ( Bazin, B; Beaufils, M; Breart, G; Capitant, C; Paris, J; Uzan, S, 1991) |
| "A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia." | 9.07 | Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991) |
| "A randomized, placebo-controlled, double-blind trial was carried out to evaluate the fetal benefits of low-dose aspirin (150 mg/day) as a treatment of placental insufficiency during the last trimester of pregnancy." | 9.06 | Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. ( Connelly, A; Cook, CM; Giles, WB; Thompson, RS; Trudinger, BJ, 1988) |
| " Low-dose aspirin and dipyridamole direct prostacyclin/thromboxane A2 balance in pregnancy to the dominance of prostacyclin and may thus prevent idiopathic uteroplacental insufficiency and fetal growth retardation in high-risk patients." | 9.06 | Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. ( Rotmans, N; Wallenburg, HC, 1987) |
| "For the past decades, growing attention has been given to aspirin use during pregnancy." | 9.05 | Aspirin for prevention of preeclampsia and fetal growth restriction. ( Guerby, P; Hamdi, SM; Loussert, L; Parant, O; Vayssiere, C; Vidal, F, 2020) |
| "Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration." | 9.05 | Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020) |
| "We sought to estimate the impact of aspirin dosage on the prevention of preeclampsia, severe preeclampsia, and fetal growth restriction." | 8.95 | The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. ( Bujold, E; Chaillet, N; Demers, S; Hyett, J; Nicolaides, K; Roberge, S, 2017) |
| "Low-dose aspirin (LDA) is thought to prevent preeclampsia in high-risk pregnancy, but it is not universally used out of concern for its efficacy and safety." | 8.91 | Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis. ( Deng, CY; Huang, GQ; Li, JK; Wang, XD; Xu, TT; Zhou, F, 2015) |
| "In high-risk pregnancies, early aspirin intervention starting before 16 weeks of gestation can prevent PIH, preeclampsia, IUGR, and preterm birth and help to increase the birth weight." | 8.91 | [Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis]. ( Wu, H; Yao, S; Yu, Y, 2015) |
| "To estimate the effect of low-dose aspirin started in early pregnancy on the incidence of preeclampsia and intrauterine growth restriction (IUGR)." | 8.86 | Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. ( Audibert, F; Bujold, E; Bureau, M; Forest, JC; Giguère, Y; Lacasse, Y; Marcoux, S; Roberge, S, 2010) |
| "To perform a meta-analysis determining the association of low-dose aspirin treatment with subsequent abruptio placentae or perinatal mortality." | 8.79 | Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality. ( Cliver, SP; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995) |
| "To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)." | 8.31 | The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023) |
| "To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy." | 8.12 | Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022) |
| "The objective of the study was to compare the efficacy of low-molecular weight heparin (LMWH) alone and use in the combination with aspirin in the treatment of fetal growth restriction (FGR) patients." | 8.12 | Comparison of Low Molecular Weight Heparin Used alone or Combined with Aspirin in the Treatment of Fetal Growth Restriction. ( He, S; Liang, L, 2022) |
| "Aspirin has been shown to reduce prevalence of both early-onset pre-eclampsia (ePET) and fetal growth restriction (FGR)." | 8.02 | Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13 ( Emeto, T; Hyett, J; O'Brien, C; Park, F; Phung, J, 2021) |
| "A previous pilot study showed that pravastatin supplementation improved pregnancy outcomes in women with obstetric antiphospholipid syndrome (OAPS) that developed placental insufficiency despite standard of care treatment low molecular weight heparin plus low dose aspirin (LMWH + LDA)." | 7.96 | Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism. ( Contento, G; Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J; Varoudi, K, 2020) |
| "Prenatal exposure to ozone has been linked to low birth weight in people and fetal growth restriction in rats." | 7.91 | Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats. ( Dye, JA; Farraj, AK; Henriquez, AR; Jarrell, LT; Kodavanti, UP; Ledbetter, AD; Miller, CN; Richards, JH; Schaldweiler, M; Snow, SJ; Stewart, EJ, 2019) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 7.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome." | 7.70 | Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998) |
| "To describe patterns of prescription in the Netherlands of low-dose aspirin in pregnancy." | 7.68 | Low-dose aspirin in pregnancy: changes in patterns of prescription in The Netherlands. ( Bremer, HA; Wallenburg, HC, 1993) |
| "Low dose Aspirin in pregnancy reduces the incidence of intra uterine growth retardation (IUGR) and pregnancy induced hypertension (PIH) in women at risk for these complications." | 7.68 | Low dose aspirin in pregnancy: a clinical and biochemical study of effects on the newborn. ( Foschini, M; Frusca, T; Soregaroli, M; Tarantini, M; Valcamonico, A, 1993) |
| "To determine whether aspirin therapy in women at risk of pre-eclampsia alters in vitro platelet aggregation." | 7.68 | Changes in platelet reactivity following aspirin treatment for pre-eclampsia. ( Elder, MG; Sullivan, MH, 1993) |
| "To determine whether the beneficial effects of aspirin in the treatment of Doppler umbilical placental insufficiency correlate with the maternal pressor response to angiotensin infusion." | 7.68 | Angiotensin sensitivity predicts aspirin benefit in placental insufficiency. ( Cook, CM; Trudinger, BJ, 1993) |
| "Treatment with prednisone and aspirin appears to be efficacious, safe, and economic in the prevention of pregnancy loss and fetal growth retardation in patients with aCL." | 7.68 | Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. ( Angel, J; Espinoza, LR; Hubble, CL; Jara, LJ; Martínez-Osuna, P; O'Brien, W; Saway, S; Seleznick, MJ; Silveira, LH, 1992) |
| " Many studies have suggested that treatment with low-dose aspirin and steroids is effective in preventing pregnancy loss or pre-eclampsia, but the mechanism has not been established." | 7.68 | [A trial of low-dose aspirin therapy in high-risk pregnancy]. ( Mochizuki, M; Morikawa, H; Ohashi, M; Takashima, M; Yamasaki, M, 1992) |
| "Pregnancy in sickle cell disease is fraught with many complications including pre-eclampsia (PE) and intrauterine growth restriction (IUGR)." | 7.01 | Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol). ( Adeyemo, TA; Afolabi, BB; Babah, OA; Ezeaka, CV; Nwaiwu, O; Odukoya, OO; Ogunnaike, BA; Oshodi, YA, 2021) |
| "Placental insufficiency affects about 10% of pregnancies and can lead to pre-eclampsia, fetal growth restriction, and preterm birth." | 6.82 | The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review. ( Bussolaro, S; Fantasia, I; Rolnik, DL; Stampalija, T, 2022) |
| "The trial enrolled 139 women at risk of preeclampsia or IUGR, with abnormal uterine artery Doppler findings that included the presence of unilateral or bilateral diastolic notch, high resistance index (RI), or high pulsatility index (PI) at 14-16 weeks of gestation." | 6.71 | Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. ( Ebrashy, A; Ibrahim, M; Marzook, A; Yousef, D, 2005) |
| "Aspirin was not associated with a significant increase in placental haemorrhages or in bleeding during preparation for epidural anaesthesia, but there was a slight increase in use of blood transfusion after delivery." | 6.67 | CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. ( , 1994) |
| "The occurrences of IUGR and preeclampsia in the study group (7." | 6.67 | [Prevention of fetal growth retardation by low dose aspirin]. ( Li, WJ; Wang, ZH, 1993) |
| "For the prevention of fetal growth restriction, a recent large-study level meta-analysis and individual patient data meta-analysis confirm that aspirin modestly reduces small-for-gestational-age pregnancy in women at high risk (relative risk, 0." | 6.58 | The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. ( David, AL; Groom, KM, 2018) |
| "Aspirin has been widely prescribed since the 1980's to prevent pre-eclampsia, intra-uterine growth retardation and fetal death of vascular origin." | 6.55 | [Aspirin: Indications and use during pregnancy]. ( Belhomme, N; Doudnikoff, C; Henriot, B; Isly, H; Jego, P; Polard, E, 2017) |
| "Outcomes included preeclampsia (mild and severe) and SGA neonates." | 6.53 | Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis. ( Bergeron, TS; Bujold, E; Carpentier, C; McCaw-Binns, A; Roberge, S; Sibai, B, 2016) |
| "Outcomes included preeclampsia, severe preeclampsia, and SGA." | 6.53 | Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. ( Bujold, E; McCaw-Binns, A; Roberge, S; Sibai, B, 2016) |
| "Low-dose aspirin significantly reduced preeclampsia risk in both East Asians (OR = 0." | 6.53 | Preventing preeclampsia and its fetal complications with low-dose aspirin in East Asians and non-East Asians:A systematic review and meta-analysis. ( Gan, J; He, H; Qi, H, 2016) |
| "Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality." | 6.50 | Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. ( Henderson, JT; O'Connor, E; Rowland, MG; Senger, CA; Thompson, JH; Whitlock, EP, 2014) |
| "On the basis of the hypothesis that preeclampsia is at least partially caused by an increase in thromboxane A2, some studies attempted to correct this pathologic condition by pharmacologic manipulation with low-dose aspirin." | 6.38 | Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. ( Dekker, GA; Sibai, BM, 1993) |
| "To assess the impact of low-dose aspirin (LDA) starting in early pregnancy on delaying preterm hypertensive disorders of pregnancy." | 5.69 | Aspirin delays the onset of hypertensive disorders of pregnancy among nulliparous pregnant women: A secondary analysis of the ASPIRIN trial. ( Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Koso-Thomas, M; Krebs, NF; Lokangaka, A; McClure, EM; Metgud, MC; Moore, J; Mwenechanya, M; Nielsen, E; Patel, A; Saleem, S; Silver, R; Somannavar, MS; Tshefu, A, 2023) |
| " The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage." | 5.41 | Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023) |
| "To establish the clinical heterogeneity among the clinical practice guidelines (CPGs) on aspirin use in pregnancy and to investigate the quality of these CPGs." | 5.41 | Clinical practice guidelines on the use of aspirin in pregnancy: Systematic review. ( Alameddine, S; D'Antonio, F; Di Girolamo, R; Khalil, A; Liberati, M; Maruotti, GM; Rizzo, G; Santilli, F, 2023) |
| " The subjects of the study were randomly assigned into two groups of intervention and control to receive either 80 mg of aspirin or placebo daily during the pregnancy." | 5.34 | The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia. ( Abdi, N; Alavi, A; Asadi, N; Hessami, K; Kasraeian, M; Rozrokh, A; Vafaei, H; Zare, S, 2020) |
| "We observed no significant difference in UtA-PI between the two doses of aspirin, but we observed low rates of fetal growth restriction and preterm and early-onset preeclampsia (all less than 5%)." | 5.34 | A Pilot Randomized Trial Comparing the Effects of 80 versus 160 mg of Aspirin on Midtrimester Uterine Artery Pulsatility Index in Women with a History of Preeclampsia. ( Bujold, E; Côté, S; Ferreira, E; Girard, M; Guerby, P; Leclair, G; Roberge, S; Tapp, S, 2020) |
| "We propose a three armed multi-center open-labeled randomized control trial of; (i) routine LDA, (ii) no aspirin, and (iii) LDA on the basis of a positive first trimester pre-eclampsia screening test." | 5.22 | An open-label randomized-controlled trial of low dose aspirin with an early screening test for pre-eclampsia and growth restriction (TEST): Trial protocol. ( Breathnach, F; Culliton, M; Dicker, P; Downey, P; Malone, FD; McAuliffe, FM; McCormack, D; McParland, P; Mone, F; Mulcahy, C; Stanton, A; Tully, E, 2016) |
| " We included randomized controlled trials reporting on health-related outcomes in children (aged > 28 days) exposed to aspirin versus placebo or no treatment during pregnancy." | 5.12 | Long-term health and neurodevelopment in children after antenatal exposure to low-dose aspirin for the prevention of preeclampsia and fetal growth restriction: A systematic review of randomized controlled trials. ( de Boer, MA; Finken, MJJ; Ket, JCF; Landman, AJEMC; Leemhuis, AG; Oudijk, MA; Painter, RC; van 't Hooft, J; van Limburg Stirum, EVJ, 2021) |
| "The use of low dose aspirin (LDA) has become routine in prenatal care for a variety of diagnoses, most importantly in women with a history of preeclampsia and associated poor pregnancy outcomes." | 5.12 | Low-dose aspirin in pregnancy: who? when? how much? and why? ( Dom, AM; Mather, AR; Thorburg, LL, 2021) |
| " We found elevated values of indices of oxidative stress in the blood serum of pregnant women with IUGR: increased levels of malondialdehyde and 4-hydroxyalkenals, decreased activity of alpha-1-antitrypsin and decreased total antioxidant capacity of the serum, with respect to healthy pregnancy." | 5.12 | Indices of oxidative stress in pregnancy with fetal growth restriction. ( Bartosz, G; Karowicz-Bilinska, A; Kedziora-Kornatowska, K, 2007) |
| " Since low doses of aspirin could improve the utero-placental circulation (by shifting the prostacyclin/thromboxane A2 balance), we have evaluated the impact of low-dose aspirin treatment of IUGR during pregnancy on umbilical (UA) and middle cerebral artery (MCA) blood flow." | 5.11 | [The impact of low-dose aspirin therapy on umbilical and middle cerebral artery blood flow in pregnancy complicated by idiopathic intrauterine growth restriction]. ( Gottwald, L; Kalinka, J; Laudański, T; Lech, W; Nowakowski, M; Zdziennicki, A, 2004) |
| "To assess the effectiveness of a pre-eclampsia prevention strategy based on routine uterine artery Doppler flow velocity waveform examination during the second trimester of pregnancy, followed by a prescription for 100 mg aspirin in the case of abnormal Doppler findings." | 5.10 | Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 2). ( Breart, G; Delcourt, YM; Goeusse, P; Houfflin-Debarge, V; Lequien, P; Malek, YM; Puech, F; Quandalle, F; Subtil, D; Uzan, S, 2003) |
| "The treatment with low doses of aspirin reduces the proportion of SGA babies and increases birthweight in the case of a diagnosed fetal growth retardation." | 5.09 | [Evaluation of the effectiveness of a low-dose aspirin in the treatment of intrauterine growth retardation (IUGR)]. ( Hanke, W; Kalinka, J; Laudański, T; Sieroszewski, P; Suzin, J, 1999) |
| "To investigate the effect of low-dose, slow-release aspirin in reducing the incidence and/or severity of pregnancy complications in women identified as high risk of developing problems associated with uteroplacental insufficiency, namely pre-eclampsia or delivering a small-for-gestational age (SGA) baby." | 5.09 | A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. ( Aquilina, J; Campbell, S; England, P; Harrington, K; Kurdi, W, 2000) |
| "Daily administration of low-dose aspirin during the second and third trimesters of pregnancy does not alter uteroplacental or fetoplacental hemodynamics and does not cause moderate or severe constriction of the ductus arteriosus." | 5.09 | Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. ( Erdmann, M; Grab, D; Kreienberg, R; Lang, D; Muche, R; Oberhoffer, R; Paulus, WE; Terinde, R, 2000) |
| "To assess whether systematic screening with an uterine artery Doppler in low risk pregnant women followed by the prescription of low dose aspirin in cases with abnormal results reduced the incidence of intrauterine growth restriction and pre-eclampsia." | 5.09 | Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. ( Aboulker, D; Bréart, G; Bucourt, M; Goffinet, F; Papiernik, E; Paris-Llado, J; Uzan, M, 2001) |
| "Aspirin therapy increased birth weight in all women, especially in women with high human chorionic gonadotropin levels, partly by increasing gestational age at delivery." | 5.08 | The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levels. ( DuBard, MB; Goldenberg, RL; Hauth, JC; Lea, C; Wenstrom, KD, 1995) |
| "To determine any benefits or risks, expressed in early childhood, of low dose aspirin treatment in pregnancies at high risk of complications due to pre-eclampsia or intrauterine growth retardation." | 5.08 | Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. ( , 1995) |
| "To determine the effectiveness of low dose aspirin in women at high risk of adverse outcomes associated with pre-eclampsia." | 5.08 | ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. ( , 1996) |
| "The purpose of this study was to investigate the hypothesis that maternal administration of 100mg aspirin each day will improve birth-weight and other measures of neonatal size when given as a treatment to pregnancies complicated by fetal growth restriction and umbilical-placental insufficiency." | 5.08 | Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. ( Evans, SF; Godfrey, M; Newnham, JP; Phillips, J; Walters, BJ, 1995) |
| "The use of low-dose aspirin for the prevention and treatment of pre-eclampsia and intrauterine growth restriction has been studied extensively during the last 10 years." | 5.08 | Effect on fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia and intrauterine growth restriction: Doppler flow study. ( Bar, J; Fisch, B; Hod, M; Kaplan, B; Meizner, I; Pardo, J; Rabinerson, D, 1997) |
| "To investigate whether low dose aspirin medication given to primiparous women provides benefit in preventing pre-eclampsia or intrauterine growth retardation." | 5.08 | A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. ( Golding, J, 1998) |
| "Meta-analysis of data from several controlled trials has shown that low-dose aspirin reduces the risk of pregnancy-induced hypertension (PIH) and intrauterine growth retardation (IUGR) in women at high risk of these disorders." | 5.07 | Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. ( , 1993) |
| "The efficacy of low-dose aspirin in preventing fetal growth retardation was tested in a randomised, placebo-controlled, double-blind trial." | 5.07 | Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. ( Bazin, B; Beaufils, M; Breart, G; Capitant, C; Paris, J; Uzan, S, 1991) |
| "A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia." | 5.07 | Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991) |
| "A randomized, placebo-controlled, double-blind trial was carried out to evaluate the fetal benefits of low-dose aspirin (150 mg/day) as a treatment of placental insufficiency during the last trimester of pregnancy." | 5.06 | Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. ( Connelly, A; Cook, CM; Giles, WB; Thompson, RS; Trudinger, BJ, 1988) |
| " Low-dose aspirin and dipyridamole direct prostacyclin/thromboxane A2 balance in pregnancy to the dominance of prostacyclin and may thus prevent idiopathic uteroplacental insufficiency and fetal growth retardation in high-risk patients." | 5.06 | Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. ( Rotmans, N; Wallenburg, HC, 1987) |
| "To perform a meta-analysis and meta-regression of randomized controlled trials (RCTs) to evaluate the impact of low-dose aspirin (LDA) on perinatal outcome, independent of its effect on pre-eclampsia (PE), preterm birth and low birth weight." | 5.05 | Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression. ( Hartel, G; Kumar, S; Robertson, NT; Turner, JM, 2020) |
| "For the past decades, growing attention has been given to aspirin use during pregnancy." | 5.05 | Aspirin for prevention of preeclampsia and fetal growth restriction. ( Guerby, P; Hamdi, SM; Loussert, L; Parant, O; Vayssiere, C; Vidal, F, 2020) |
| "Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration." | 5.05 | Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020) |
| " There is general consensus between guidelines (at least 4 of 6 guidelines in agreement) in early pregnancy risk selection, and use of low-dose aspirin for women with major risk factors for placental insufficiency." | 4.98 | Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. ( Anderson, NH; Figueras, F; McCowan, LM, 2018) |
| "We sought to estimate the impact of aspirin dosage on the prevention of preeclampsia, severe preeclampsia, and fetal growth restriction." | 4.95 | The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. ( Bujold, E; Chaillet, N; Demers, S; Hyett, J; Nicolaides, K; Roberge, S, 2017) |
| "Low-dose aspirin (LDA) is thought to prevent preeclampsia in high-risk pregnancy, but it is not universally used out of concern for its efficacy and safety." | 4.91 | Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis. ( Deng, CY; Huang, GQ; Li, JK; Wang, XD; Xu, TT; Zhou, F, 2015) |
| "In high-risk pregnancies, early aspirin intervention starting before 16 weeks of gestation can prevent PIH, preeclampsia, IUGR, and preterm birth and help to increase the birth weight." | 4.91 | [Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis]. ( Wu, H; Yao, S; Yu, Y, 2015) |
| " Current treatment of patients with antiphospholipid syndrome (APS) during pregnancy with heparin and aspirin can act by preventing clot formation and improving live birth rates, but other obstetric morbidities remain high, especially in patients with a history of thrombotic events." | 4.90 | Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? ( de Jesús, GR; de Jesús, NR; Levy, RA; Rodrigues, G, 2014) |
| "Databases were searched for keywords related to aspirin and pregnancy." | 4.89 | Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. ( Bujold, E; Demers, S; Nicolaides, KH; Roberge, S; Villa, P, 2013) |
| "To estimate the effect of low-dose aspirin started in early pregnancy on the incidence of preeclampsia and intrauterine growth restriction (IUGR)." | 4.86 | Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. ( Audibert, F; Bujold, E; Bureau, M; Forest, JC; Giguère, Y; Lacasse, Y; Marcoux, S; Roberge, S, 2010) |
| "To perform a meta-analysis determining the association of low-dose aspirin treatment with subsequent abruptio placentae or perinatal mortality." | 4.79 | Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality. ( Cliver, SP; Cutter, GR; Goldenberg, RL; Hauth, JC; Parker, CR, 1995) |
| "The results of four large controlled clinical trials, encompassing over 13,000 pregnant women, indicate that low-dose aspirin is of benefit in the prevention of pre-eclampsia in women at high risk." | 4.79 | Low-dose aspirin therapy in obstetrics. ( Wallenburg, HC, 1995) |
| "We searched 18 medical databases, including MEDLINE since 1964 and EMBASE since 1974, review articles and the references from each retrieved report to identify all studies evaluating the effect of aspirin in pregnancy and including both intrauterine growth retardation and perinatal mortality as outcome measures." | 4.79 | A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. ( Egarter, C; Husslein, P; Kaider, A; Leitich, H; Schemper, M, 1997) |
| "l-Arginine, aspirin and vitamin D are promising, high-potential preventative agents for fetal growth restriction." | 4.31 | Analysis of a maternal health medicines pipeline database 2000-2021: New candidates for the prevention and treatment of fetal growth restriction. ( Ammerdorffer, A; Goldstein, M; Gülmezoglu, AM; Hastie, R; Lim, S; McDougall, ARA; Ricci, C; Rushwan, S; Tong, S; Tuttle, A; Vogel, JP, 2023) |
| "To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)." | 4.31 | The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023) |
| "To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy." | 4.12 | Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022) |
| "The objective of the study was to compare the efficacy of low-molecular weight heparin (LMWH) alone and use in the combination with aspirin in the treatment of fetal growth restriction (FGR) patients." | 4.12 | Comparison of Low Molecular Weight Heparin Used alone or Combined with Aspirin in the Treatment of Fetal Growth Restriction. ( He, S; Liang, L, 2022) |
| "A retrospective study of 32 women with severe recurrent placenta-mediated complications (preeclampsia with severe features, placental abruption, severe intrauterine growth retardation or intra uterine fetal death) in spite of treatment with low molecular weight heparin and low dose aspirin in previous pregnancy." | 4.12 | Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study. ( Asher-Landsberg, J; Gamzu, R; Kliger, C; Kupferminc, MJ; Rimon, E; Skornick-Rapaport, A; Yogev, Y, 2022) |
| "Aspirin has been shown to reduce prevalence of both early-onset pre-eclampsia (ePET) and fetal growth restriction (FGR)." | 4.02 | Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13 ( Emeto, T; Hyett, J; O'Brien, C; Park, F; Phung, J, 2021) |
| "A previous pilot study showed that pravastatin supplementation improved pregnancy outcomes in women with obstetric antiphospholipid syndrome (OAPS) that developed placental insufficiency despite standard of care treatment low molecular weight heparin plus low dose aspirin (LMWH + LDA)." | 3.96 | Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism. ( Contento, G; Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J; Varoudi, K, 2020) |
| "Prenatal exposure to ozone has been linked to low birth weight in people and fetal growth restriction in rats." | 3.91 | Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats. ( Dye, JA; Farraj, AK; Henriquez, AR; Jarrell, LT; Kodavanti, UP; Ledbetter, AD; Miller, CN; Richards, JH; Schaldweiler, M; Snow, SJ; Stewart, EJ, 2019) |
| "To examine the effect of first-trimester screening for pre-eclampsia (PE) on the prediction of delivering a small-for-gestational-age (SGA) neonate and the effect of prophylactic use of aspirin on the prevention of SGA." | 3.88 | Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. ( Akolekar, R; Cicero, S; de Paco Matallana, C; Greco, E; Janga, D; Jani, JC; Molina, FS; Nicolaides, KH; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Singh, M; Syngelaki, A; Tan, MY; Wright, D, 2018) |
| "Low-dose aspirin has been demonstrated to reduce the incidence of preeclampsia and fetal growth restriction in at-risk populations." | 3.85 | Should we recommend universal aspirin for all pregnant women? ( McAuliffe, FM; McParland, P; Mone, F; Mulcahy, C, 2017) |
| "This prospective study aimed to evaluate pregnancy outcome and complications in women with recurrent pregnancy loss (RPL) and protein S (PS) deficiency, who received low dose aspirin (LDA) or LDA plus heparin (LDA/H) therapies." | 3.83 | Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss. ( Deguchi, M; Ebina, Y; Morizane, M; Shinozaki, N; Tanimura, K; Yamada, H, 2016) |
| " She was started on 100 mg of aspirin, 20 mg of prednisolone and 20 mg of subcutaneous low-molecular-weight heparin daily for her fourth pregnancy." | 3.83 | Repeated failed non-invasive prenatal testing in a woman with immune thrombocytopenia and antiphospholipid syndrome: lessons learnt. ( Hui, CY; Tan, EL; Tan, LK; Tan, WC, 2016) |
| "Indications for aspirin use during pregnancy were previous HD, FGR, intrauterine fetal death or current maternal disease." | 3.83 | Aspirin adherence during high-risk pregnancies, a questionnaire study. ( Abheiden, CN; de Boer, MA; de Vries, JI; Fuijkschot, WW; Thijs, A; van Reuler, AV, 2016) |
| "To identify patients at very high risk for adverse pregnancy outcome (APO) at the 20- to 23-week scan and to assess the effectiveness of Aspirin (ASS) and low molecular weight heparin (LMWH) starting after this examination." | 3.79 | Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects. ( Becker, R; Bittner, U; Fangerau, H; Keller, T; Kiesewetter, H, 2013) |
| "Two study groups were distinguished - with untreated IUGR and with IUGR treated with the acetylsalicylic acid and L-arginine and the control group with correct fetal growth and course of pregnancy Marked microscope preparations from placental samples were made with specific antibodies for MMP-9 and TIMP-2." | 3.78 | [Expression of metalloproteinase MMP-9 and tissue inhibitor of metalloproteinase TIMP-2 in placenta of pregnant women with intrauterine growth restriction]. ( Karowicz-Bilińska, A; Kobos, J; Kowalska-Koprek, U; Pasiński, J; Swierczewski, A, 2012) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 3.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "To elucidate the efficacy of the treatment using a Japanese-modified Chinese herbal medicine, Sairei-to, and low-dose aspirin with or without a corticosteroid hormone for the patients with adverse pregnancy histories positive for anti-phospholipid antibodies." | 3.73 | Prophylactic therapy for patients with reproductive failure who were positive for anti-phospholipid antibodies. ( Ishii, K; Kikuchi, A; Nonaka, T; Ooki, I; Takakuwa, K; Tamura, M; Tamura, N; Tanaka, K, 2006) |
| "We report the cases of two patients who had a favorable outcome with aspirin and corticosteroid therapy during pregnancy for chronic villitis of unknown etiology complicated by labor asphyxia and further intrauterine fetal demise in one gravida 3 patient and for chronic intervillositis of unknown etiology diagnosed after three perinatal deaths in another patient (gravida 4)." | 3.73 | [Combining corticosteroid and aspirin for the prevention of recurrent villitis or intervillositis of unknown etiology]. ( Alnoukari, F; Barrier, J; Boog, G; Jossic, F; Le Vaillant, C; Muller, JY, 2006) |
| "The aim of this study was the evaluation of carbonyl group concentration in blood serum in normal pregnancy and in women with IUGR treated by L-arginine and acetylsalicylic acid." | 3.72 | [Plasma carbonyl group concentration in pregnant women with IUGR treated by L-arginine and acetylsalicylic acid]. ( Karowicz-Bilińska, A; Kowalska-Koprek, U; Marszałek, M; Sieroszewski, P; Suzin, J, 2004) |
| " If thrombophilia was diagnosed on the basis of hyperhomocysteinemia, the treatment consisted of aspirin, pyridoxine and folic acid, instead." | 3.71 | Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women. ( Aardenburg, R; de Leeuw, PW; Ekhart, TH; Peeters, LL; Spaanderman, ME; van der Heijden, OW; van Eyck, J; van Eyndhoven, HW, 2001) |
| "To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome." | 3.70 | Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998) |
| "To our knowledge, this is the first time that a combination of aspirin and glyceryl trinitrate (GTN) has been used in the prophylaxis of preeclampsia and fetal growth retardation, and their use associated with not only Doppler screening of the uterine arteries but also regular Doppler follow-up of the fetal arterial and venous circulation." | 3.70 | A novel approach to the management of pregnancies complicated by uteroplacental insufficiency and previous stillbirth. ( Black, RS; Campbell, S; Lees, CC; Oyelese, KO, 1998) |
| " The success rate was higher when treatment was given because of previous poor pregnancy outcomes than when it was given for other indications, and the patients with successful therapy had started aspirin earlier than had those with therapy failure (17." | 3.70 | Effect of aspirin in pregnant women is dependent on increase in bleeding time. ( Beaufils, M; Dumont, A; Flahault, A; Uzan, S; Verdy, E, 1999) |
| "To describe patterns of prescription in the Netherlands of low-dose aspirin in pregnancy." | 3.68 | Low-dose aspirin in pregnancy: changes in patterns of prescription in The Netherlands. ( Bremer, HA; Wallenburg, HC, 1993) |
| "Low dose Aspirin in pregnancy reduces the incidence of intra uterine growth retardation (IUGR) and pregnancy induced hypertension (PIH) in women at risk for these complications." | 3.68 | Low dose aspirin in pregnancy: a clinical and biochemical study of effects on the newborn. ( Foschini, M; Frusca, T; Soregaroli, M; Tarantini, M; Valcamonico, A, 1993) |
| "To determine whether aspirin therapy in women at risk of pre-eclampsia alters in vitro platelet aggregation." | 3.68 | Changes in platelet reactivity following aspirin treatment for pre-eclampsia. ( Elder, MG; Sullivan, MH, 1993) |
| "To determine whether the beneficial effects of aspirin in the treatment of Doppler umbilical placental insufficiency correlate with the maternal pressor response to angiotensin infusion." | 3.68 | Angiotensin sensitivity predicts aspirin benefit in placental insufficiency. ( Cook, CM; Trudinger, BJ, 1993) |
| "Treatment with prednisone and aspirin appears to be efficacious, safe, and economic in the prevention of pregnancy loss and fetal growth retardation in patients with aCL." | 3.68 | Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. ( Angel, J; Espinoza, LR; Hubble, CL; Jara, LJ; Martínez-Osuna, P; O'Brien, W; Saway, S; Seleznick, MJ; Silveira, LH, 1992) |
| " Many studies have suggested that treatment with low-dose aspirin and steroids is effective in preventing pregnancy loss or pre-eclampsia, but the mechanism has not been established." | 3.68 | [A trial of low-dose aspirin therapy in high-risk pregnancy]. ( Mochizuki, M; Morikawa, H; Ohashi, M; Takashima, M; Yamasaki, M, 1992) |
| "Pregnancy-induced hypertension (PIH) and preeclampsia develop when an imbalance occurs between prostacyclin (PGI2) and thromboxane A2 (TXA2) production." | 3.68 | [Effect of low-dose aspirin therapy on utero-placental blood flow and malondialdehyde (MDA) as an indicator of its therapeutic effect]. ( Iwata, I; Iwata, M; Masuhiro, K; Mitsuda, N; Nishino, E; Takagi, T; Tanizawa, O, 1990) |
| " During their next pregnancy, the patients were treated with 40 to 50 mg of prednisone per day and 81 mg of aspirin per day." | 3.67 | Obstetric complications associated with the lupus anticoagulant. ( Branch, DW; Hershgold, E; Kochenour, NK; Scott, JR, 1985) |
| "ASA use during pregnancy has benefits beyond reducing the risk of pre-eclampsia." | 3.01 | The Role of Acetylsalicylic Acid in the Prevention of Pre-Eclampsia, Fetal Growth Restriction, and Preterm Birth. ( Berger, R; Hinz, B; Stubert, J, 2023) |
| "Pregnancy in sickle cell disease is fraught with many complications including pre-eclampsia (PE) and intrauterine growth restriction (IUGR)." | 3.01 | Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol). ( Adeyemo, TA; Afolabi, BB; Babah, OA; Ezeaka, CV; Nwaiwu, O; Odukoya, OO; Ogunnaike, BA; Oshodi, YA, 2021) |
| "Placental insufficiency affects about 10% of pregnancies and can lead to pre-eclampsia, fetal growth restriction, and preterm birth." | 2.82 | The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review. ( Bussolaro, S; Fantasia, I; Rolnik, DL; Stampalija, T, 2022) |
| "The prevention of fetal growth restriction (FGR) is challenging in clinical practice." | 2.72 | Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis. ( Avagliano, L; Bettiol, A; Crescioli, G; Emmi, G; Lombardi, N; Ravaldi, C; Urban, ML; Vannacci, A; Virgili, G, 2021) |
| "Women with a prior pregnancy affected by FGR have a 20% to 30% risk of recurrence, but effective preventive strategies are lacking." | 2.72 | Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies. ( Blue, NR; Page, JM; Silver, RM, 2021) |
| "The trial enrolled 139 women at risk of preeclampsia or IUGR, with abnormal uterine artery Doppler findings that included the presence of unilateral or bilateral diastolic notch, high resistance index (RI), or high pulsatility index (PI) at 14-16 weeks of gestation." | 2.71 | Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. ( Ebrashy, A; Ibrahim, M; Marzook, A; Yousef, D, 2005) |
| "The reduction in the incidence of intrauterine growth retardation (2." | 2.70 | Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. ( Iso-Mustajärvi, M; Kujansuu, E; Mäenpää, J; Vainio, M, 2002) |
| "Aspirin was not associated with a significant increase in placental haemorrhages or in bleeding during preparation for epidural anaesthesia, but there was a slight increase in use of blood transfusion after delivery." | 2.67 | CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. ( , 1994) |
| "Aspirin treatment did not affect the relation between the Doppler indices and these outcomes in the logistic regression model." | 2.67 | The predictive value of umbilical artery Doppler studies for preeclampsia or fetal growth retardation in a preeclampsia prevention trial. ( Atkinson, MW; Copper, RL; Goldenberg, RL; Hauth, JC; Maher, JE; Owen, J, 1994) |
| "The occurrences of IUGR and preeclampsia in the study group (7." | 2.67 | [Prevention of fetal growth retardation by low dose aspirin]. ( Li, WJ; Wang, ZH, 1993) |
| "Normal pregnancy is a complex and dynamic process that requires significant adaptation from the maternal system." | 2.66 | Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond. ( Doherty, A; Kingdom, JC; McLaughlin, K, 2020) |
| "Placenta-mediated pregnancy complications are clinically important conditions and include preeclampsia, placental abruption, intrauterine growth restriction, and late fetal loss." | 2.66 | Understanding and Preventing Placenta-Mediated Pregnancy Complications. ( Blondon, M; Ní Áinle, F; Skeith, L, 2020) |
| "The pregnancy was normal in 54% of patients in group A and 23% in group B (p less than 0." | 2.65 | [Controlled trial of preventive treatment of preeclampsia. Preliminary results]. ( Beaufils, M; Colau, JC; Donsimoni, R; Uzan, S, 1984) |
| "For the prevention of fetal growth restriction, a recent large-study level meta-analysis and individual patient data meta-analysis confirm that aspirin modestly reduces small-for-gestational-age pregnancy in women at high risk (relative risk, 0." | 2.58 | The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. ( David, AL; Groom, KM, 2018) |
| "Aspirin has been widely prescribed since the 1980's to prevent pre-eclampsia, intra-uterine growth retardation and fetal death of vascular origin." | 2.55 | [Aspirin: Indications and use during pregnancy]. ( Belhomme, N; Doudnikoff, C; Henriot, B; Isly, H; Jego, P; Polard, E, 2017) |
| "Outcomes included preeclampsia (mild and severe) and SGA neonates." | 2.53 | Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis. ( Bergeron, TS; Bujold, E; Carpentier, C; McCaw-Binns, A; Roberge, S; Sibai, B, 2016) |
| "Outcomes included preeclampsia, severe preeclampsia, and SGA." | 2.53 | Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. ( Bujold, E; McCaw-Binns, A; Roberge, S; Sibai, B, 2016) |
| "Low-dose aspirin significantly reduced preeclampsia risk in both East Asians (OR = 0." | 2.53 | Preventing preeclampsia and its fetal complications with low-dose aspirin in East Asians and non-East Asians:A systematic review and meta-analysis. ( Gan, J; He, H; Qi, H, 2016) |
| "Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality." | 2.50 | Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. ( Henderson, JT; O'Connor, E; Rowland, MG; Senger, CA; Thompson, JH; Whitlock, EP, 2014) |
| "Preeclampsia, intrauterine growth restriction (IUGR), and placental abruption are obstetrical conditions that constitute the syndrome of ischemic placental disease or IPD, the leading cause of indicated preterm birth and an important cause of neonatal morbidity and mortality." | 2.50 | Prediction and prevention of ischemic placental disease. ( Cleary, KL; Friedman, AM, 2014) |
| "The primary outcome was preeclampsia." | 2.45 | Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. ( Bujold, E; Forest, JC; Giguère, Y; Lacasse, Y; Morency, AM; Roberge, S, 2009) |
| "Women with a history of previous preeclampsia are at increased risk of preeclampsia and other adverse pregnancy outcomes in subsequent pregnancies." | 2.44 | Prediction and prevention of recurrent preeclampsia. ( Barton, JR; Sibai, BM, 2008) |
| "The choice of therapy for fetal growth restriction (FGR) depends on the nature of the insult that led to the development of FGR." | 2.43 | Prenatal therapy for fetal growth restriction. ( Figueroa, R; Maulik, D, 2006) |
| "Recently, the thrombophilias have been revealed as risk factors for severe preeclampsia, abruptio placentae, fetal growth retardation, abortion and still birth as well." | 2.42 | [Anticoagulation and antiaggregation during pregnancy]. ( Biasiutti, FD; Strebel, JK, 2003) |
| "The risk of preeclampsia and placental insufficiency was substantial and occurred in 50% of patients." | 2.42 | Antiphospholipid syndrome in obstetrics. ( Heilmann, L; Pollow, K; von Tempelhoff, GF, 2003) |
| "Many authors relate this factor with preeclampsia, intrauterine fetal growth retardation, spontaneous abortion, unexplained cases of still birth, placental abruption, and thromboembolic complications during and after parturition." | 2.42 | [Factor V Leiden mutation and pregnancy complications]. ( Abraitis, V; Mockeviciene, A; Mongirdiene, A, 2003) |
| "If diagnosed and treated early in pregnancy with low-dose aspirin and subcutaneous heparin the outlook for a successful pregnancy is much improved." | 2.41 | A literature review on the antiphospholipid syndrome and the effect on childbearing. ( Vials, JM, 2001) |
| "Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)." | 2.39 | Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996) |
| "Preeclampsia is characterized by a functional imbalance between vascular prostacyclin and thromboxane A2 production." | 2.38 | [Acetylsalicylic acid in pregnancy]. ( Egarter, C; Husslein, P; Karas, H, 1993) |
| "On the basis of the hypothesis that preeclampsia is at least partially caused by an increase in thromboxane A2, some studies attempted to correct this pathologic condition by pharmacologic manipulation with low-dose aspirin." | 2.38 | Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. ( Dekker, GA; Sibai, BM, 1993) |
| "The principle underlying preventive treatment of fetal intrauterine growth retardation can only be considered after defining various groups that are at risk and early screening based on the obstetric history, biological tests, and recently using flow rates with Doppler techniques." | 2.38 | [Fetal growth retardation: prevention. Review of the literature]. ( Boulot, P; Giacalone, PL; Hedon, B; Laffargue, F; Viala, JL, 1992) |
| " Clinicians who decide to manage complicated or potentially complicated patients with chronic administration of aspirin must continue to study these mothers, fetuses, and neonates intensively and to document their results." | 2.38 | Low-dose aspirin to improve perinatal outcome. ( Barton, JR; Sibai, BM, 1991) |
| "Antiphospholipid syndrome is an autoimmune, hypercoagulable state that is caused by antiphospholipid antibodies." | 1.46 | Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. ( Berghella, V; Bernabini, D; Dall'Asta, A; Eke, AC; Facchinetti, F; Ghi, T; Hoxha, A; Martinelli, P; Maruotti, GM; Monari, F; Rizzo, G; Rizzo, N; Roman, A; Ruffatti, A; Saccone, G; Sarno, L; Schuit, E; Simonazzi, G; Visentin, S; Xodo, S, 2017) |
| "(2) Influence of treatment on the pregnancy outcomes and complications: 24 APS patients were given the treatment of aspirin or aspirin combined with low molecular weight heparin, and 30 patients received no treatment." | 1.40 | [Pregnancy outcome in 54 patients with antiphospholipid syndrome: a retrospective clinical study]. ( Deng, XL; Liu, XY; Zheng, XJ, 2014) |
| "Intrauterine growth restriction is connected with high rate of prematurity and perinatal mortality." | 1.32 | [Analysis of 8-isoprostane concentration as a marker of oxidative stress in pregnant women diagnosed with IUGR]. ( Karowicz-Bilińska, A; Kowalska-Koprek, U; Sieroszewski, P; Suzin, J, 2003) |
| "Both COX inhibitors were toxic to dams in the highest doses evaluated, which caused a significantly greater incidence of intrauterine growth retardation and developmental variations." | 1.32 | Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL:(WI)WUBR rats. ( Burdan, F, 2004) |
| "A newborn had a subdural hematoma detected with a prenatal ultrasonography at 31 weeks' gestation, probably in keeping with the regular treatment of AAS." | 1.30 | [Favorable outcome of a subdural hematoma diagnosed in utero]. ( Daussac, E; Lafont, M; Lamarque, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (6.38) | 18.7374 |
| 1990's | 63 (33.51) | 18.2507 |
| 2000's | 38 (20.21) | 29.6817 |
| 2010's | 47 (25.00) | 24.3611 |
| 2020's | 28 (14.89) | 2.80 |
| Authors | Studies |
|---|---|
| Landman, AJEMC | 1 |
| van Limburg Stirum, EVJ | 1 |
| de Boer, MA | 2 |
| van 't Hooft, J | 1 |
| Ket, JCF | 1 |
| Leemhuis, AG | 1 |
| Finken, MJJ | 1 |
| Oudijk, MA | 1 |
| Painter, RC | 1 |
| Hastie, R | 2 |
| Tong, S | 3 |
| Wikström, AK | 1 |
| Walker, SP | 2 |
| Lindquist, A | 1 |
| Cluver, CA | 1 |
| Kupka, E | 1 |
| Bergman, L | 1 |
| Hesselman, S | 1 |
| He, S | 2 |
| Liang, L | 1 |
| Fantasia, I | 1 |
| Bussolaro, S | 1 |
| Stampalija, T | 1 |
| Rolnik, DL | 2 |
| Kawaguchi, H | 1 |
| Kanagawa, T | 1 |
| Yamamoto, R | 1 |
| Sasahara, J | 1 |
| Okamoto, Y | 1 |
| Mitsuda, N | 2 |
| Ishii, K | 2 |
| D'Antonio, F | 4 |
| Khalil, A | 4 |
| Rizzo, G | 5 |
| Fichera, A | 3 |
| Herrera, M | 3 |
| Buca, D | 3 |
| Morelli, R | 3 |
| Cerra, C | 3 |
| Orabona, R | 3 |
| Acuti Martellucci, C | 3 |
| Flacco, ME | 3 |
| Prefumo, F | 3 |
| Di Girolamo, R | 1 |
| Alameddine, S | 1 |
| Santilli, F | 1 |
| Maruotti, GM | 2 |
| Liberati, M | 1 |
| Lim, S | 1 |
| McDougall, ARA | 1 |
| Goldstein, M | 1 |
| Tuttle, A | 1 |
| Ammerdorffer, A | 1 |
| Rushwan, S | 1 |
| Ricci, C | 1 |
| Gülmezoglu, AM | 1 |
| Vogel, JP | 1 |
| Joudi, N | 1 |
| Rode, M | 1 |
| Cardoso, MIMP | 1 |
| Rezende, KBC | 1 |
| Da Matta, FG | 1 |
| Saunders, C | 1 |
| Cardoso, FFO | 1 |
| Costa Junior, IB | 1 |
| Gama, LB | 1 |
| Amim, J | 1 |
| Bornia, RG | 1 |
| Stubert, J | 1 |
| Hinz, B | 1 |
| Berger, R | 1 |
| Kavi, A | 1 |
| Hoffman, MK | 1 |
| Somannavar, MS | 1 |
| Metgud, MC | 1 |
| Goudar, SS | 1 |
| Moore, J | 1 |
| Nielsen, E | 1 |
| Goco, N | 1 |
| McClure, EM | 1 |
| Lokangaka, A | 1 |
| Tshefu, A | 1 |
| Bauserman, M | 1 |
| Mwenechanya, M | 1 |
| Chomba, E | 1 |
| Carlo, WA | 1 |
| Figueroa, L | 1 |
| Krebs, NF | 1 |
| Jessani, S | 1 |
| Saleem, S | 1 |
| Goldenberg, RL | 4 |
| Das, P | 1 |
| Patel, A | 1 |
| Hibberd, PL | 1 |
| Esamai, F | 1 |
| Bucher, S | 1 |
| Koso-Thomas, M | 1 |
| Silver, R | 1 |
| Derman, RJ | 1 |
| Turner, JM | 1 |
| Robertson, NT | 1 |
| Hartel, G | 1 |
| Kumar, S | 1 |
| Loussert, L | 1 |
| Vidal, F | 1 |
| Parant, O | 1 |
| Hamdi, SM | 1 |
| Vayssiere, C | 1 |
| Guerby, P | 2 |
| Theilen, LH | 1 |
| Campbell, HD | 1 |
| Mumford, SL | 1 |
| Purdue-Smithe, AC | 1 |
| Sjaarda, LA | 1 |
| Perkins, NJ | 1 |
| Radoc, JG | 1 |
| Silver, RM | 2 |
| Schisterman, EF | 1 |
| Ghazanfarpour, M | 1 |
| Sathyapalan, T | 1 |
| Banach, M | 1 |
| Jamialahmadi, T | 1 |
| Sahebkar, A | 1 |
| Doherty, A | 1 |
| McLaughlin, K | 1 |
| Kingdom, JC | 1 |
| Skeith, L | 1 |
| Blondon, M | 1 |
| Ní Áinle, F | 1 |
| Abdi, N | 1 |
| Rozrokh, A | 1 |
| Alavi, A | 1 |
| Zare, S | 1 |
| Vafaei, H | 1 |
| Asadi, N | 1 |
| Kasraeian, M | 1 |
| Hessami, K | 1 |
| Tapp, S | 2 |
| Girard, M | 1 |
| Roberge, S | 8 |
| Côté, S | 1 |
| Ferreira, E | 2 |
| Leclair, G | 1 |
| Bujold, E | 9 |
| Lefkou, E | 1 |
| Varoudi, K | 1 |
| Pombo, J | 1 |
| Jurisic, A | 1 |
| Jurisic, Z | 1 |
| Contento, G | 1 |
| Girardi, G | 1 |
| Park, F | 1 |
| O'Brien, C | 1 |
| Phung, J | 1 |
| Emeto, T | 1 |
| Hyett, J | 2 |
| Bettiol, A | 1 |
| Avagliano, L | 1 |
| Lombardi, N | 1 |
| Crescioli, G | 1 |
| Emmi, G | 1 |
| Urban, ML | 1 |
| Virgili, G | 1 |
| Ravaldi, C | 1 |
| Vannacci, A | 1 |
| Mather, AR | 1 |
| Dom, AM | 1 |
| Thorburg, LL | 1 |
| Blue, NR | 1 |
| Page, JM | 1 |
| Kupferminc, MJ | 1 |
| Kliger, C | 1 |
| Rimon, E | 1 |
| Asher-Landsberg, J | 1 |
| Skornick-Rapaport, A | 1 |
| Gamzu, R | 1 |
| Yogev, Y | 1 |
| Cruz-Lemini, M | 1 |
| Vázquez, JC | 1 |
| Ullmo, J | 1 |
| Llurba, E | 1 |
| Afolabi, BB | 1 |
| Babah, OA | 1 |
| Adeyemo, TA | 1 |
| Odukoya, OO | 1 |
| Ezeaka, CV | 1 |
| Nwaiwu, O | 1 |
| Oshodi, YA | 1 |
| Ogunnaike, BA | 1 |
| Calhoun, B | 1 |
| Hoover, E | 1 |
| Seybold, D | 1 |
| Broce, M | 1 |
| Hill, A | 1 |
| Schaible, B | 1 |
| Bracero, LA | 1 |
| Poon, LC | 2 |
| Käehne, LV | 1 |
| Rørbye, C | 1 |
| Abdulghani, S | 1 |
| Moretti, F | 1 |
| Gruslin, A | 1 |
| Grynspan, D | 1 |
| McMaster-Fay, RA | 1 |
| Hyett, JA | 1 |
| Ali, MK | 2 |
| Abbas, AM | 1 |
| Yosef, AH | 1 |
| Bahloul, M | 1 |
| Iriye, BK | 1 |
| Gregory, KD | 1 |
| Saade, GR | 1 |
| Grobman, WA | 1 |
| Brown, HL | 1 |
| Rosenberg, K | 1 |
| Belhomme, N | 1 |
| Doudnikoff, C | 1 |
| Polard, E | 1 |
| Henriot, B | 1 |
| Isly, H | 1 |
| Jego, P | 1 |
| Groom, KM | 1 |
| David, AL | 2 |
| Stanescu, AD | 1 |
| Banica, R | 1 |
| Sima, RM | 1 |
| Ples, L | 1 |
| McCowan, LM | 2 |
| Figueras, F | 1 |
| Anderson, NH | 1 |
| Nawathe, A | 1 |
| Tan, MY | 1 |
| Syngelaki, A | 1 |
| de Paco Matallana, C | 1 |
| Akolekar, R | 1 |
| Cicero, S | 1 |
| Janga, D | 1 |
| Singh, M | 1 |
| Molina, FS | 1 |
| Persico, N | 1 |
| Jani, JC | 1 |
| Plasencia, W | 1 |
| Greco, E | 1 |
| Papaioannou, G | 1 |
| Wright, D | 1 |
| Nicolaides, KH | 2 |
| Miller, CN | 1 |
| Kodavanti, UP | 1 |
| Stewart, EJ | 1 |
| Schaldweiler, M | 1 |
| Richards, JH | 1 |
| Ledbetter, AD | 1 |
| Jarrell, LT | 1 |
| Snow, SJ | 1 |
| Henriquez, AR | 1 |
| Farraj, AK | 1 |
| Dye, JA | 1 |
| Voutetakis, A | 1 |
| Pervanidou, P | 1 |
| Kanaka-Gantenbein, C | 1 |
| de Jesús, GR | 1 |
| Rodrigues, G | 1 |
| de Jesús, NR | 1 |
| Levy, RA | 1 |
| Henderson, JT | 1 |
| Whitlock, EP | 1 |
| O'Connor, E | 1 |
| Senger, CA | 1 |
| Thompson, JH | 1 |
| Rowland, MG | 1 |
| Zheng, XJ | 1 |
| Deng, XL | 1 |
| Liu, XY | 1 |
| Friedman, AM | 1 |
| Cleary, KL | 1 |
| Voelker, R | 1 |
| Mutlu, I | 1 |
| Mutlu, MF | 1 |
| Biri, A | 1 |
| Bulut, B | 1 |
| Erdem, M | 1 |
| Erdem, A | 1 |
| Xu, TT | 1 |
| Zhou, F | 1 |
| Deng, CY | 1 |
| Huang, GQ | 1 |
| Li, JK | 1 |
| Wang, XD | 1 |
| Abheiden, C | 1 |
| Van Hoorn, ME | 1 |
| Hague, WM | 1 |
| Kostense, PJ | 1 |
| van Pampus, MG | 1 |
| de Vries, J | 1 |
| Yao, S | 1 |
| Wu, H | 1 |
| Yu, Y | 1 |
| Kim, MY | 1 |
| Buyon, JP | 1 |
| Guerra, MM | 1 |
| Rana, S | 1 |
| Zhang, D | 1 |
| Laskin, CA | 1 |
| Petri, M | 1 |
| Lockshin, MD | 1 |
| Sammaritano, LR | 1 |
| Branch, DW | 2 |
| Porter, TF | 1 |
| Merrill, JT | 1 |
| Stephenson, MD | 1 |
| Gao, Q | 1 |
| Karumanchi, SA | 1 |
| Salmon, JE | 1 |
| Bergeron, TS | 1 |
| Carpentier, C | 1 |
| Sibai, B | 2 |
| McCaw-Binns, A | 2 |
| Etwel, F | 1 |
| Koren, G | 1 |
| Shinozaki, N | 1 |
| Ebina, Y | 1 |
| Deguchi, M | 1 |
| Tanimura, K | 1 |
| Morizane, M | 1 |
| Yamada, H | 1 |
| Odibo, AO | 1 |
| Gan, J | 1 |
| He, H | 1 |
| Qi, H | 1 |
| Mone, F | 2 |
| Mulcahy, C | 2 |
| McParland, P | 2 |
| Stanton, A | 1 |
| Culliton, M | 1 |
| Downey, P | 1 |
| McCormack, D | 1 |
| Tully, E | 1 |
| Dicker, P | 1 |
| Breathnach, F | 1 |
| Malone, FD | 1 |
| McAuliffe, FM | 2 |
| Neykova, K | 1 |
| Dimitrova, V | 1 |
| Dimitrov, R | 1 |
| Vakrilova, L | 1 |
| Nicolaides, K | 1 |
| Demers, S | 2 |
| Chaillet, N | 2 |
| Hui, CY | 1 |
| Tan, WC | 1 |
| Tan, EL | 1 |
| Tan, LK | 1 |
| Abheiden, CN | 1 |
| van Reuler, AV | 1 |
| Fuijkschot, WW | 1 |
| de Vries, JI | 2 |
| Thijs, A | 1 |
| Amin, ME | 1 |
| Amin, AF | 1 |
| Abd El Aal, DEM | 1 |
| Mol, BW | 2 |
| Saccone, G | 1 |
| Berghella, V | 1 |
| Ghi, T | 1 |
| Simonazzi, G | 1 |
| Rizzo, N | 1 |
| Facchinetti, F | 1 |
| Dall'Asta, A | 1 |
| Visentin, S | 1 |
| Sarno, L | 1 |
| Xodo, S | 1 |
| Bernabini, D | 1 |
| Monari, F | 1 |
| Roman, A | 1 |
| Eke, AC | 1 |
| Hoxha, A | 1 |
| Ruffatti, A | 1 |
| Schuit, E | 1 |
| Martinelli, P | 1 |
| Barton, JR | 2 |
| Sibai, BM | 5 |
| Morris, RK | 1 |
| Cnossen, JS | 1 |
| Langejans, M | 1 |
| Robson, SC | 1 |
| Kleijnen, J | 1 |
| Ter Riet, G | 1 |
| van der Post, JA | 1 |
| Khan, KS | 2 |
| Morency, AM | 1 |
| Lacasse, Y | 2 |
| Forest, JC | 3 |
| Giguère, Y | 3 |
| Bureau, M | 1 |
| Audibert, F | 2 |
| Marcoux, S | 1 |
| Rey, E | 2 |
| Fraser, WD | 1 |
| Swierczewski, A | 1 |
| Kobos, J | 1 |
| Pasiński, J | 1 |
| Kowalska-Koprek, U | 4 |
| Karowicz-Bilińska, A | 5 |
| Cuckle, H | 1 |
| von Dadelszen, P | 1 |
| Ghidini, A | 1 |
| Villa, P | 1 |
| Becker, R | 1 |
| Keller, T | 1 |
| Kiesewetter, H | 1 |
| Fangerau, H | 1 |
| Bittner, U | 1 |
| Somerset, D | 1 |
| Coomarasamy, A | 1 |
| Gee, H | 1 |
| Smith, JH | 1 |
| Stone, S | 2 |
| Hunt, BJ | 2 |
| Seed, PT | 2 |
| Parmar, K | 1 |
| Khamashta, MA | 2 |
| Poston, L | 2 |
| Biasiutti, FD | 1 |
| Strebel, JK | 1 |
| Subtil, D | 1 |
| Goeusse, P | 1 |
| Houfflin-Debarge, V | 1 |
| Puech, F | 1 |
| Lequien, P | 1 |
| Breart, G | 8 |
| Uzan, S | 11 |
| Quandalle, F | 1 |
| Delcourt, YM | 1 |
| Malek, YM | 1 |
| Heilmann, L | 1 |
| von Tempelhoff, GF | 1 |
| Pollow, K | 1 |
| Langford, K | 1 |
| Abraitis, V | 1 |
| Mongirdiene, A | 1 |
| Mockeviciene, A | 1 |
| Suzin, J | 3 |
| Sieroszewski, P | 3 |
| Marszałek, M | 1 |
| Kalinka, J | 2 |
| Gottwald, L | 1 |
| Nowakowski, M | 1 |
| Lech, W | 1 |
| Zdziennicki, A | 1 |
| Laudański, T | 2 |
| Burdan, F | 1 |
| Verspyck, E | 1 |
| Marpeau, L | 1 |
| Ebrashy, A | 1 |
| Ibrahim, M | 1 |
| Marzook, A | 1 |
| Yousef, D | 1 |
| Haram, K | 1 |
| Søfteland, E | 1 |
| Bukowski, R | 1 |
| Figueroa, R | 1 |
| Maulik, D | 1 |
| Kuś, E | 1 |
| De Santis, M | 1 |
| Cavaliere, AF | 1 |
| Straface, G | 1 |
| Di Gianantonio, E | 1 |
| Caruso, A | 1 |
| Takakuwa, K | 1 |
| Ooki, I | 1 |
| Nonaka, T | 1 |
| Tamura, N | 1 |
| Kikuchi, A | 1 |
| Tamura, M | 1 |
| Tanaka, K | 1 |
| Boog, G | 1 |
| Le Vaillant, C | 1 |
| Alnoukari, F | 1 |
| Jossic, F | 1 |
| Barrier, J | 1 |
| Muller, JY | 1 |
| Kornacka, MK | 1 |
| Bokiniec, R | 1 |
| Kedziora-Kornatowska, K | 1 |
| Bartosz, G | 1 |
| Hossain, N | 1 |
| Paidas, MJ | 1 |
| Leduc, L | 1 |
| Dubois, E | 1 |
| Takser, L | 1 |
| David, M | 1 |
| Beaufils, M | 7 |
| Donsimoni, R | 2 |
| Colau, JC | 2 |
| Goodlin, RC | 1 |
| Wenstrom, KD | 1 |
| Hauth, JC | 3 |
| DuBard, MB | 1 |
| Lea, C | 1 |
| Lavanya, R | 1 |
| Pratap, K | 1 |
| Parker, CR | 1 |
| Cutter, GR | 1 |
| Cliver, SP | 1 |
| Wallenburg, HC | 5 |
| Darling, M | 2 |
| Higgins, J | 1 |
| Hamed, MR | 1 |
| al-Assy, YS | 1 |
| Ezzeldin, E | 1 |
| Valensise, H | 1 |
| Romanini, C | 1 |
| Lorentzen, B | 2 |
| Henriksen, T | 2 |
| Gonser, M | 1 |
| Marzusch, K | 1 |
| Louden, KA | 2 |
| Crawford, MA | 1 |
| Karas, H | 1 |
| Egarter, C | 2 |
| Husslein, P | 2 |
| Bremer, HA | 1 |
| Atkinson, MW | 1 |
| Maher, JE | 1 |
| Owen, J | 1 |
| Copper, RL | 1 |
| Valcamonico, A | 1 |
| Foschini, M | 1 |
| Soregaroli, M | 1 |
| Tarantini, M | 1 |
| Frusca, T | 1 |
| Wang, ZH | 1 |
| Li, WJ | 1 |
| Sullivan, MH | 2 |
| Elder, MG | 3 |
| Carp, HJ | 1 |
| Menashe, Y | 1 |
| Frenkel, Y | 1 |
| Many, A | 1 |
| Nebel, L | 1 |
| Toder, V | 1 |
| Mashiach, S | 1 |
| Dekker, GA | 2 |
| Cook, CM | 2 |
| Trudinger, BJ | 2 |
| Endresen, M | 1 |
| Clausen, T | 1 |
| Haddad, B | 3 |
| Uzan, M | 4 |
| Newnham, JP | 1 |
| Godfrey, M | 1 |
| Walters, BJ | 1 |
| Phillips, J | 1 |
| Evans, SF | 1 |
| Wang, Z | 1 |
| Li, W | 1 |
| Paniel, BJ | 1 |
| Griesshammer, M | 1 |
| Heimpel, H | 1 |
| Pearson, TC | 1 |
| Leitich, H | 1 |
| Kaider, A | 1 |
| Schemper, M | 1 |
| Bar, J | 2 |
| Hod, M | 2 |
| Pardo, J | 1 |
| Fisch, B | 1 |
| Rabinerson, D | 1 |
| Kaplan, B | 1 |
| Meizner, I | 1 |
| Burnog, T | 1 |
| Pollack, RN | 1 |
| Yaffe, H | 1 |
| Divon, MY | 1 |
| Golding, J | 1 |
| Ural, S | 1 |
| Nagey, DA | 1 |
| Clark, NA | 1 |
| de Swiet, M | 2 |
| Nelson-Piercy, C | 1 |
| Riyazi, N | 1 |
| Leeda, M | 1 |
| Huijgens, PC | 1 |
| van Geijn, HP | 1 |
| Oyelese, KO | 1 |
| Black, RS | 1 |
| Lees, CC | 1 |
| Campbell, S | 2 |
| Dumont, A | 2 |
| Flahault, A | 1 |
| Verdy, E | 1 |
| Hanke, W | 1 |
| Harding, J | 1 |
| Roberts, A | 1 |
| Barker, S | 1 |
| Ford, C | 1 |
| Stewart, A | 1 |
| Lafont, M | 1 |
| Lamarque, M | 1 |
| Daussac, E | 1 |
| Harrington, K | 1 |
| Kurdi, W | 1 |
| Aquilina, J | 1 |
| England, P | 1 |
| Grab, D | 1 |
| Paulus, WE | 1 |
| Erdmann, M | 1 |
| Terinde, R | 1 |
| Oberhoffer, R | 1 |
| Lang, D | 1 |
| Muche, R | 1 |
| Kreienberg, R | 1 |
| Trudinger, B | 1 |
| Merviel, P | 1 |
| Berkane, N | 1 |
| Mashiah, R | 1 |
| Cohen-Sacher, B | 1 |
| Orvieto, R | 1 |
| Ben-Rafael, Z | 1 |
| Lahav, J | 1 |
| Spaanderman, ME | 1 |
| Aardenburg, R | 1 |
| Ekhart, TH | 1 |
| van Eyndhoven, HW | 1 |
| van der Heijden, OW | 1 |
| van Eyck, J | 1 |
| de Leeuw, PW | 1 |
| Peeters, LL | 1 |
| Goffinet, F | 1 |
| Aboulker, D | 1 |
| Paris-Llado, J | 1 |
| Bucourt, M | 1 |
| Papiernik, E | 1 |
| Vials, JM | 1 |
| Vainio, M | 1 |
| Kujansuu, E | 1 |
| Iso-Mustajärvi, M | 1 |
| Mäenpää, J | 1 |
| van Kessel, PH | 1 |
| Boulot, P | 1 |
| Giacalone, PL | 1 |
| Hedon, B | 1 |
| Laffargue, F | 1 |
| Viala, JL | 1 |
| Paris, J | 2 |
| Silveira, LH | 1 |
| Hubble, CL | 1 |
| Jara, LJ | 1 |
| Saway, S | 1 |
| Martínez-Osuna, P | 1 |
| Seleznick, MJ | 1 |
| Angel, J | 1 |
| O'Brien, W | 1 |
| Espinoza, LR | 1 |
| van Hof, AC | 1 |
| Ubachs, JM | 1 |
| van Wersch, JW | 1 |
| Shuev, BV | 1 |
| Dotts, IB | 1 |
| Takashima, M | 1 |
| Yamasaki, M | 1 |
| Ohashi, M | 1 |
| Morikawa, H | 1 |
| Mochizuki, M | 1 |
| Bazin, B | 2 |
| Capitant, C | 1 |
| Davies, NJ | 1 |
| Farquharson, RG | 1 |
| Walkinshaw, Sa | 1 |
| Fay, TN | 1 |
| Wallenburg, CS | 1 |
| Sureau, C | 1 |
| Keirse, MJ | 1 |
| Seneviratne, HR | 1 |
| Weerasinghe, WM | 1 |
| Nishino, E | 1 |
| Takagi, T | 1 |
| Masuhiro, K | 1 |
| Iwata, I | 1 |
| Iwata, M | 1 |
| Tanizawa, O | 1 |
| Danays, T | 1 |
| Robertson, A | 1 |
| Elder, MA | 1 |
| Flloyd, E | 1 |
| Hawkins, DF | 1 |
| Rotmans, N | 2 |
| Thompson, RS | 1 |
| Giles, WB | 1 |
| Connelly, A | 1 |
| Falconer, J | 1 |
| Pineo, G | 1 |
| Blahey, W | 1 |
| Bowen, T | 1 |
| Docksteader, B | 1 |
| Jadusingh, I | 1 |
| Lubbe, WF | 1 |
| Liggins, GC | 1 |
| Scott, JR | 1 |
| Kochenour, NK | 1 |
| Hershgold, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Transplacental Aspirin Therapy for Early Onset Fetal Growth[NCT04557475] | Phase 3 | 0 participants (Actual) | Interventional | 2022-06-11 | Withdrawn (stopped due to We are modifying this trial's protocol and will resubmit a new application at a later date.) | ||
| Correlation Between Pulmonary Artery Doppler And Other Ultrasonographic Markers With Neonatal Outcome In Placenta Accreta Spectrum Patients[NCT04911322] | 71 participants (Actual) | Observational | 2021-08-15 | Completed | |||
| Correlation Between Pulmonary Artery Doppler And Neonatal Outcome In Hypertensive Disorders Of Pregnancy[NCT05793125] | 72 participants (Anticipated) | Observational | 2023-04-03 | Recruiting | |||
| Low Dose Aspirin in the Prevention of Preeclampsia in Chinese Pregnant Women.[NCT02797249] | Phase 3 | 1,000 participants (Actual) | Interventional | 2016-12-07 | Completed | ||
| Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-05-28 | Recruiting | ||
| Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial[NCT05253781] | Phase 3 | 476 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | ||
| Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia[NCT04797949] | Phase 4 | 156 participants (Anticipated) | Interventional | 2021-03-03 | Recruiting | ||
| Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)[NCT00198068] | 700 participants (Anticipated) | Observational | 2003-09-30 | Recruiting | |||
| An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction[NCT03674606] | Phase 4 | 546 participants (Actual) | Interventional | 2014-02-01 | Completed | ||
| A Randomized Controlled Trial Comparing Low Doses Of Aspirin In The Prevention Of Preeclampsia (ASAPP)[NCT04070573] | Phase 3 | 400 participants (Anticipated) | Interventional | 2019-10-21 | Enrolling by invitation | ||
| A Pragmatic Randomized Study Comparing 81 mg Aspirin Versus 162 mg Aspirin in the Prevention of Preeclampsia During Pregnancy[NCT04158830] | Phase 4 | 0 participants (Actual) | Interventional | 2020-06-01 | Withdrawn (stopped due to PI is no longer at this University.) | ||
| 162 mg of Aspirin for Prevention of Preeclampsia[NCT05221164] | Phase 4 | 200 participants (Anticipated) | Interventional | 2021-07-06 | Recruiting | ||
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| [NCT02696577] | Phase 2 | 68 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Efficacy L-arginine + L-citrulline as a Dietary Supplement vs Placebo for Weight Gain in Fetus With a Decrease in Their Growth Curve in the Third Trimester of Pregnancy[NCT05029778] | Phase 4 | 41 participants (Anticipated) | Interventional | 2021-10-20 | Not yet recruiting | ||
| Prospective Validation of Prediction Algorithms for Preeclampsia in the First-trimester of Pregnancy[NCT03554681] | 10,935 participants (Actual) | Observational | 2016-12-31 | Completed | |||
| STUDY PROTOCOL FOR A PROSPECTIVE, MULTICENTRE, COHORT STUDY: Preeclampsia Sequential Screening Using Angiogenic Factors During First Trimester of Pregnancy (CRISP STUDY)[NCT04767438] | 6,560 participants (Anticipated) | Observational | 2021-03-31 | Not yet recruiting | |||
| Prevention of Preeclampsia With Aspirin Administered From the Beginning of Pregnancy in Recipients of Donated Oocytes.[NCT02174328] | Phase 3 | 81 participants (Actual) | Interventional | 2014-05-21 | Terminated (stopped due to Halted prematurely due to low recruitment rate.) | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Induction of Labor at Term Versus Expectant Management Among Women With Abnormal Maternal Serum Biochemical Markers: A Randomized Controlled Trial[NCT02754635] | 320 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | |||
| Serum Assessment of Preterm Birth: Outcomes Compared to Historical Controls[NCT03151330] | 2,110 participants (Anticipated) | Interventional | 2018-06-15 | Active, not recruiting | |||
| A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-hypertensive Medication and Controls[NCT00759278] | 0 participants (Actual) | Observational | 2008-08-31 | Withdrawn (stopped due to No participants) | |||
| Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)[NCT03152058] | Phase 2 | 55 participants (Anticipated) | Interventional | 2017-05-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
64 reviews available for aspirin and Fetal Growth Retardation
| Article | Year |
|---|---|
Long-term health and neurodevelopment in children after antenatal exposure to low-dose aspirin for the prevention of preeclampsia and fetal growth restriction: A systematic review of randomized controlled trials.
Topics: Aspirin; Child; Female; Fetal Growth Retardation; Humans; Infant; Infant, Newborn; Parturition; Pre- | 2021 |
The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review.
Topics: Antioxidants; Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Melatonin; Placent | 2022 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Clinical practice guidelines on the use of aspirin in pregnancy: Systematic review.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Placenta; Placenta Diseases; Platelet Aggregation | 2023 |
Aspirin in pregnancy: a review of indications, timing, dosing and efficacy.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Infant, Small for Gestational Ag | 2023 |
The Role of Acetylsalicylic Acid in the Prevention of Pre-Eclampsia, Fetal Growth Restriction, and Preterm Birth.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy; Premat | 2023 |
Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression.
Topics: Abruptio Placentae; Apgar Score; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retardation; Hum | 2020 |
Aspirin for prevention of preeclampsia and fetal growth restriction.
Topics: Angiogenesis Inducing Agents; Anticoagulants; Aspirin; Female; Fetal Growth Retardation; Gestational | 2020 |
Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses.
Topics: Abruptio Placentae; Aspirin; Female; Fetal Growth Retardation; Hemorrhage; Humans; Hypertension, Pre | 2020 |
Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond.
Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retarda | 2020 |
Understanding and Preventing Placenta-Mediated Pregnancy Complications.
Topics: Abruptio Placentae; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; | 2020 |
Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Hemorrhage; He | 2021 |
Low-dose aspirin in pregnancy: who? when? how much? and why?
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy; Pregna | 2021 |
Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies.
Topics: Adult; Anticoagulants; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retardation; Gestational A | 2021 |
Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Gestational Ag | 2022 |
[Treatment with low-dose acetylsalicylic acid can reduce risk of pre-eclampsia in high-risk pregnant women].
Topics: Aspirin; Early Medical Intervention; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Peri | 2017 |
[Aspirin: Indications and use during pregnancy].
Topics: Aspirin; Female; Fetal Death; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pregnancy, | 2017 |
The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction.
Topics: Anticoagulants; Aspirin; Female; Fetal Growth Retardation; Genetic Therapy; Heparin; Heparin, Low-Mo | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Prophylaxis and treatment of foetal growth restriction.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diet, Healthy; Female; | 2018 |
Aspirin for the Prevention of Preeclampsia and Potential Consequences for Fetal Brain Development.
Topics: Aspirin; Brain; Cyclooxygenase Inhibitors; Female; Fetal Growth Retardation; Humans; Infant, Newborn | 2019 |
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retarda | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Prediction and prevention of ischemic placental disease.
Topics: Abruptio Placentae; Anticoagulants; Ascorbic Acid; Aspirin; Calcium, Dietary; Dietary Supplements; F | 2014 |
Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Platelet Aggregation Inhibitors; | 2015 |
[Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis].
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Pre-Eclampsia; Pre | 2015 |
Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newborn; Infant, Small f | 2016 |
When positive studies of novel therapies are subsequently nullified: cumulative meta-analyses in preeclampsia.
Topics: Antioxidants; Aspirin; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Journal Impact | 2015 |
Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newborn; Infant, Small f | 2016 |
Aspirin for the Prevention of Preeclampsia and Intrauterine Growth Restriction.
Topics: Aspirin; Female; Fetal Growth Retardation; Heparin; Humans; Pre-Eclampsia; Pregnancy | 2016 |
Preventing preeclampsia and its fetal complications with low-dose aspirin in East Asians and non-East Asians:A systematic review and meta-analysis.
Topics: Asian People; Aspirin; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibitors; Pr | 2016 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
Prediction and prevention of recurrent preeclampsia.
Topics: Adult; Antihypertensive Agents; Aspirin; Calcium, Dietary; Female; Fetal Growth Retardation; Heparin | 2008 |
Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis.
Topics: alpha-Fetoproteins; Aspirin; Biomarkers; Chorionic Gonadotropin; Estriol; Female; Fetal Growth Retar | 2008 |
Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibitors; Pre-Eclampsia; P | 2009 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis.
Topics: Aspirin; Female; Fetal Death; Fetal Growth Retardation; Humans; Perinatal Mortality; Platelet Aggreg | 2013 |
[Anticoagulation and antiaggregation during pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Abruptio Placentae; Administration, Oral; Adult; | 2003 |
Antiphospholipid syndrome in obstetrics.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Annexin A5; Antibodies, Anticardiolipin; Anticoagu | 2003 |
[Factor V Leiden mutation and pregnancy complications].
Topics: Abortion, Spontaneous; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; Factor V; Fem | 2003 |
[Thrombophilias and vascular placental pathology. A survey of the literature].
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cohort Studies; | 2005 |
Intrauterine growth restriction.
Topics: Adrenal Cortex Hormones; Amniotic Fluid; Aspirin; Bed Rest; Female; Fetal Development; Fetal Growth | 2006 |
Prenatal therapy for fetal growth restriction.
Topics: Adrenergic beta-Agonists; Aspirin; Bed Rest; Calcium Channel Blockers; Calcium, Dietary; Diet, Sodiu | 2006 |
Inherited and acquired thrombophilia: pregnancy outcome and treatment.
Topics: Abortion, Spontaneous; Abruptio Placentae; Anticoagulants; Aspirin; Female; Fetal Growth Retardation | 2006 |
[Newborn from mother with antiphospholipid syndrome].
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Female; Fet | 2006 |
Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies.
Topics: Anticoagulants; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Heparin; Humans; Immunoglobu | 2007 |
Low-dose aspirin: lack of association with an increase in abruptio placentae or perinatal mortality.
Topics: Abruptio Placentae; Aspirin; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Incidenc | 1995 |
Low-dose aspirin therapy in obstetrics.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Randomized Controlled T | 1995 |
[Acetylsalicylic acid in pregnancy].
Topics: Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; E | 1993 |
Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials.
Topics: Angiotensin II; Aspirin; Clinical Trials as Topic; Epoprostenol; Female; Fetal Growth Retardation; H | 1993 |
[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin].
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Incidence; Odds Ratio; Patient Selection; Platele | 1996 |
Essential thrombocythemia and pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di | 1996 |
A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Fetal Growth Retardation; Humans; Infant M | 1997 |
Therapy for intrauterine growth restriction: current options and future directions.
Topics: Adrenergic beta-Agonists; Aspirin; Atrial Natriuretic Factor; Bed Rest; Cyclooxygenase Inhibitors; D | 1997 |
Chronic hypertension in pregnancy.
Topics: Abruptio Placentae; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin | 1999 |
[Aspirin: a return to the source rather than a big disappointment].
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pregnancy Complications | 2000 |
A literature review on the antiphospholipid syndrome and the effect on childbearing.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Embolism; Female; Fetal Death; Fetal Diseases; F | 2001 |
[Fetal growth retardation: prevention. Review of the literature].
Topics: Adrenergic beta-Agonists; Aspirin; Evaluation Studies as Topic; Female; Fetal Growth Retardation; ga | 1992 |
[Aspirin as a cyclooxygenase inhibitor in various complications of the gestational period].
Topics: Aspirin; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Epoprostenol; Female; Fetal Gr | 1992 |
An aspirin a day to prevent prematurity.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Health Status Indicators; Humans; Obstetric | 1992 |
[Is prevention of pre-eclampsia possible?].
Topics: Antihypertensive Agents; Aspirin; Diuretics; Eclampsia; Female; Fetal Growth Retardation; Humans; Hy | 1991 |
Low-dose aspirin to improve perinatal outcome.
Topics: Antibodies; Aspirin; Blood Coagulation Factors; Cardiolipins; Female; Fetal Growth Retardation; Fetu | 1991 |
Platelet anti-aggregatory therapy in pregnancy: another role for low dose aspirin?
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibitors; Pre-Eclampsia; P | 1990 |
Lupus anticoagulant and pregnancy.
Topics: Aspirin; Autoantibodies; Blood Coagulation Factors; Female; Fetal Death; Fetal Diseases; Fetal Growt | 1985 |
41 trials available for aspirin and Fetal Growth Retardation
| Article | Year |
|---|---|
Aspirin delays the onset of hypertensive disorders of pregnancy among nulliparous pregnant women: A secondary analysis of the ASPIRIN trial.
Topics: Aspirin; Child; Child Health; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Indu | 2023 |
The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia.
Topics: Adult; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pregnancy-Associ | 2020 |
A Pilot Randomized Trial Comparing the Effects of 80 versus 160 mg of Aspirin on Midtrimester Uterine Artery Pulsatility Index in Women with a History of Preeclampsia.
Topics: Aspirin; Canada; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Infant, | 2020 |
Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol).
Topics: Anemia, Sickle Cell; Aspirin; Female; Fetal Growth Retardation; Humans; Nigeria; Placenta; Pre-Eclam | 2021 |
The effect of low-dose aspirin on fetal weight of idiopathic asymmetrically intrauterine growth restricted fetuses with abnormal umbilical artery Doppler indices: a randomized clinical trial.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibit | 2018 |
Low dose aspirin for preventing fetal growth restriction: a randomised trial.
Topics: Adult; Aspirin; Birth Weight; Drug Administration Schedule; Female; Fetal Growth Retardation; Gestat | 2018 |
Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results.
Topics: Adult; Anticoagulants; Aspirin; Birth Weight; Blood Flow Velocity; Drug Therapy, Combination; Female | 2016 |
An open-label randomized-controlled trial of low dose aspirin with an early screening test for pre-eclampsia and growth restriction (TEST): Trial protocol.
Topics: Aspirin; Early Diagnosis; Female; Fetal Growth Retardation; Humans; Mass Screening; Medication Adher | 2016 |
Evaluation of the effectiveness of low-dose aspirin and omega 3 in treatment of asymmetrically intrauterine growth restriction: A randomized clinical trial.
Topics: Adult; Aspirin; Fatty Acids, Omega-3; Female; Fetal Growth Retardation; Fetal Weight; Fibrinolytic A | 2017 |
Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 2).
Topics: Adult; Arteries; Aspirin; Female; Fetal Growth Retardation; Humans; Placental Circulation; Platelet | 2003 |
[The impact of low-dose aspirin therapy on umbilical and middle cerebral artery blood flow in pregnancy complicated by idiopathic intrauterine growth restriction].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Flow Velocity; Dose-Response Relation | 2004 |
Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial.
Topics: Aspirin; Case-Control Studies; Echocardiography, Doppler; Female; Fetal Growth Retardation; Humans; | 2005 |
Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial.
Topics: Aspirin; Case-Control Studies; Echocardiography, Doppler; Female; Fetal Growth Retardation; Humans; | 2005 |
Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial.
Topics: Aspirin; Case-Control Studies; Echocardiography, Doppler; Female; Fetal Growth Retardation; Humans; | 2005 |
Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial.
Topics: Aspirin; Case-Control Studies; Echocardiography, Doppler; Female; Fetal Growth Retardation; Humans; | 2005 |
Indices of oxidative stress in pregnancy with fetal growth restriction.
Topics: Adult; alpha 1-Antitrypsin; Arginine; Aspirin; Biomarkers; Female; Fetal Growth Retardation; Humans; | 2007 |
[Controlled trial of preventive treatment of preeclampsia. Preliminary results].
Topics: Adult; Aspirin; Blood Volume; Clinical Trials as Topic; Dipyridamole; Female; Fetal Growth Retardati | 1984 |
The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levels.
Topics: Adolescent; Adult; Aspirin; Birth Weight; Chi-Square Distribution; Chorionic Gonadotropin; Double-Bl | 1995 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
Uterine Doppler in the identification of patients at risk for hypertension and IUGR.
Topics: Aspirin; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Hypertension; Infant, Newbor | 1994 |
[Comments: low-dose aspirin in pregnant women].
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy | 1994 |
Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy.
Topics: Adolescent; Adult; Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; P | 1993 |
The predictive value of umbilical artery Doppler studies for preeclampsia or fetal growth retardation in a preeclampsia prevention trial.
Topics: Adult; Aspirin; Diastole; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Logistic Mo | 1994 |
[Prevention of fetal growth retardation by low dose aspirin].
Topics: Adolescent; Adult; Aspirin; Blood Flow Velocity; Double-Blind Method; Female; Fetal Growth Retardati | 1993 |
Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group.
Topics: Aspirin; Body Height; Body Weight; Canada; Cohort Studies; Developmental Disabilities; Double-Blind | 1995 |
ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group.
Topics: Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Follow-Up Studies; Humans; Obs | 1996 |
Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Placent | 1995 |
Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Placent | 1995 |
Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Placent | 1995 |
Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Placent | 1995 |
A prospective randomized placebo-controlled trial of low-dose aspirin for prevention of intra-uterine growth retardation.
Topics: Adolescent; Adult; Aspirin; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Placenta; | 1996 |
Effect on fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia and intrauterine growth restriction: Doppler flow study.
Topics: Adult; Aspirin; Blood Circulation; Female; Fetal Blood; Fetal Growth Retardation; Fetus; Humans; Pla | 1997 |
A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group.
Topics: Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Follow-Up Studies; Hum | 1998 |
[Evaluation of the effectiveness of a low-dose aspirin in the treatment of intrauterine growth retardation (IUGR)].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Female; F | 1999 |
Administration of low-dose aspirin to mothers with small for gestational age fetuses and abnormal umbilical Doppler studies to increase birthweight: a randomised double-blind controlled trial.
Topics: Adult; Aspirin; Birth Weight; Double-Blind Method; Female; Fetal Growth Retardation; Humans; Platele | 1999 |
A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arteries; Aspirin; Delayed-Action Preparations; Fema | 2000 |
Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Flow Velocity; Cyclooxygenase Inhibitors; Do | 2000 |
Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial.
Topics: Adult; Algorithms; Aspirin; Female; Fetal Growth Retardation; Fibrinolytic Agents; Humans; Pre-Eclam | 2001 |
Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches.
Topics: Adult; Arteries; Aspirin; Birth Weight; Blood Flow Velocity; Double-Blind Method; Female; Fetal Grow | 2002 |
[Prevention of intrauterine growth retardation and pre-eclampsia by small doses of aspirin. Results of the french multicenter trial EPREDA and comparison with data in the literature; value of uterine Doppler].
Topics: Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Female; Fetal Growth Retardat | 1992 |
Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial.
Topics: Adult; Aspirin; Birth Weight; Dipyridamole; Double-Blind Method; Drug Administration Schedule; Drug | 1991 |
Low-dose aspirin and nulliparae.
Topics: Aspirin; Birth Weight; Cesarean Section; Double-Blind Method; Female; Fetal Growth Retardation; Huma | 1991 |
Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group.
Topics: Abruptio Placentae; Aspirin; Birth Weight; Dipyridamole; Double-Blind Method; Drug Combinations; Fem | 1991 |
Idiopathic recurrent fetal growth retardation and aspirin-dipyridamole therapy.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Fetal Growth Ret | 1989 |
Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency.
Topics: Adult; Aspirin; Birth Weight; Blood Flow Velocity; Clinical Trials as Topic; Double-Blind Method; Fe | 1988 |
Prospective controlled study of early antiplatelet therapy in prevention of preeclampsia.
Topics: Adult; Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Fetal Growth Retardation; Humans; Pa | 1986 |
Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole.
Topics: Adult; Aspirin; Birth Weight; Clinical Trials as Topic; Dipyridamole; Epoprostenol; Female; Fetal Gr | 1987 |
83 other studies available for aspirin and Fetal Growth Retardation
| Article | Year |
|---|---|
Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy.
Topics: Aspirin; Birth Weight; Cohort Studies; Female; Fetal Growth Retardation; Gestational Age; Humans; In | 2022 |
Comparison of Low Molecular Weight Heparin Used alone or Combined with Aspirin in the Treatment of Fetal Growth Restriction.
Topics: Aspirin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; I | 2022 |
Efficacy of discontinuing the use of low-dose aspirin at 28 weeks of gestation for preventing preeclampsia.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension; Infant, Newborn; Postpartum Hemorrh | 2022 |
Analysis of a maternal health medicines pipeline database 2000-2021: New candidates for the prevention and treatment of fetal growth restriction.
Topics: Arginine; Aspirin; Female; Fetal Growth Retardation; Humans; Maternal Health; Pregnancy; Pregnancy C | 2023 |
The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin.
Topics: Aspirin; Brazil; Female; Fetal Death; Fetal Growth Retardation; Gestational Age; Humans; Infant, New | 2023 |
Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial.
Topics: Abruptio Placentae; Adult; Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnanc | 2020 |
Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Anticoagulants; A | 2020 |
Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newborn; Infant, Small f | 2021 |
Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study.
Topics: Abruptio Placentae; Aspirin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans | 2022 |
Outcomes in an obstetrical population with hereditary thrombophilia and high tobacco use.
Topics: Adult; Anticoagulants; Aspirin; Case-Control Studies; Comorbidity; Female; Fetal Growth Retardation; | 2018 |
Re: Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study. E. Scazzocchio, D. Oros, D. Diaz, J. C. Ramirez, M. Ricart, E. Meler, R. González de Agüero, E. Gratacos and F. Fi
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Trophoblasts; Uterine Artery | 2017 |
Recurrent Massive Perivillous Fibrin Deposition and Chronic Intervillositis Treated With Heparin and Intravenous Immunoglobulin: A Case Report.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Anticoagulants; Aspirin; Chorionic Villi; Daltepar | 2017 |
Comment on: Preventing preeclampsia with aspirin: does dose or timing matter?
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibitors; Pre-Eclampsia; P | 2017 |
Quality measures in high-risk pregnancies: Executive Summary of a Cooperative Workshop of the Society for Maternal-Fetal Medicine, National Institute of Child Health and Human Development, and the American College of Obstetricians and Gynecologists.
Topics: Antibiotic Prophylaxis; Aspirin; Cesarean Section; Congresses as Topic; Female; Fetal Growth Retarda | 2017 |
Aspirin Lowers the Risk of Preeclampsia.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; Platelet Aggreg | 2017 |
Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE.
Topics: Adult; Aspirin; Biomarkers; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newbo | 2018 |
Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats.
Topics: Air Pollutants; Animals; Aspirin; Drug Administration Schedule; Female; Fetal Growth Retardation; Ox | 2019 |
[Pregnancy outcome in 54 patients with antiphospholipid syndrome: a retrospective clinical study].
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retardation; Heparin | 2014 |
USPSTF: Low-dose aspirin may help reduce risk of preeclampsia.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibit | 2014 |
Effects of anticoagulant therapy on pregnancy outcomes in patients with thrombophilia and previous poor obstetric history.
Topics: Abortion, Habitual; Anticoagulants; Apgar Score; Aspirin; Birth Weight; Blood Coagulation Factors; D | 2015 |
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Anticoagulants; Antige | 2016 |
Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Aspirin; Birth Weight; Comorbidity; Drug Th | 2016 |
[ANTITHROMBOTIC MEDICATION IN PREGNANT WOMEN WITH PREVIOUS INTRAUTERINE GROWTH RESTRICTION].
Topics: Anticoagulants; Aspirin; Birth Weight; Female; Fetal Growth Retardation; Gestational Age; Heparin, L | 2016 |
Should we recommend universal aspirin for all pregnant women?
Topics: Aspirin; Blood Pressure; Drug Resistance; Female; Fetal Growth Retardation; Humans; Medication Adher | 2017 |
Repeated failed non-invasive prenatal testing in a woman with immune thrombocytopenia and antiphospholipid syndrome: lessons learnt.
Topics: Abortion, Induced; Adult; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retardation; Gene | 2016 |
Aspirin adherence during high-risk pregnancies, a questionnaire study.
Topics: Adult; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Health Knowledge, Attitudes, Practice | 2016 |
Preventing preeclampsia with aspirin: does dose or timing matter?
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibitors; Pre-Eclampsia; P | 2017 |
Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; beta 2-Glyc | 2017 |
Prevention of adverse pregnancy outcomes with low-dose ASA in early pregnancy: new perspectives for future randomized trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Fetal Growth Retardation; Humans; Patient | 2011 |
[Expression of metalloproteinase MMP-9 and tissue inhibitor of metalloproteinase TIMP-2 in placenta of pregnant women with intrauterine growth restriction].
Topics: Adult; Arginine; Aspirin; Female; Fetal Growth Retardation; Humans; Matrix Metalloproteinase 9; Plac | 2012 |
Current controversies in prenatal diagnosis 4: pregnancy complications due to placental vascular disease (pre-eclampsia, FGR): are we ready for prevention?
Topics: Aspirin; Calcium; Female; Fetal Growth Retardation; Gestational Age; Humans; Placenta; Placenta Dise | 2013 |
Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects.
Topics: Algorithms; Anticoagulants; Aspirin; Body Mass Index; Female; Fetal Death; Fetal Growth Retardation; | 2013 |
Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches.
Topics: Animals; Arteries; Aspirin; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibitor | 2002 |
Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches.
Topics: Arteries; Aspirin; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibitors; Pre-Ec | 2002 |
Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches.
Topics: Arteries; Aspirin; Female; Fetal Growth Retardation; Humans; Meta-Analysis as Topic; Platelet Aggreg | 2002 |
Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Dalteparin; Endothelium, Vascular; F | 2003 |
Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy.
Topics: Abortion, Spontaneous; Abruptio Placentae; Adult; Antiphospholipid Syndrome; Aspirin; Female; Fetal | 2003 |
[Analysis of 8-isoprostane concentration as a marker of oxidative stress in pregnant women diagnosed with IUGR].
Topics: Adult; Arginine; Aspirin; Biomarkers; Case-Control Studies; Dinoprost; F2-Isoprostanes; Female; Feta | 2003 |
[Plasma carbonyl group concentration in pregnant women with IUGR treated by L-arginine and acetylsalicylic acid].
Topics: Adult; Arginine; Aspirin; Biomarkers; Blood Proteins; Carbon; Case-Control Studies; Enzyme-Linked Im | 2004 |
Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL:(WI)WUBR rats.
Topics: Animals; Aspirin; Body Weight; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; | 2004 |
[The total antioxidative activity measured by FRAP method in women with intrauterine growth restriction treated by L-arginine].
Topics: Adult; Arginine; Aspirin; Female; Fetal Blood; Fetal Growth Retardation; Humans; Nitric Oxide; Nitri | 2005 |
Prophylactic therapy for patients with reproductive failure who were positive for anti-phospholipid antibodies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; Aspirin; Drugs, Chinese H | 2006 |
[Combining corticosteroid and aspirin for the prevention of recurrent villitis or intervillositis of unknown etiology].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chorionic Villi; D | 2006 |
Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Female; F | 2007 |
Correction of pregnancy-related thrombocytopenia with aspirin without improvement in fetal outcome.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Death; Fetal Growth Retardation; Humans; Pl | 1983 |
Can low-dose acetylsalicylic acid cause disseminated intravascular coagulation?
Topics: Adult; Aspirin; Disseminated Intravascular Coagulation; Female; Fetal Growth Retardation; Humans; Po | 1995 |
CLASP: millstone or milestone?
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Multicenter Studies as Topic; Pre-Eclampsia; Preg | 1994 |
Influence of protein malnutrition on teratogenicity of acetylsalicylic acid in rats.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Aspirin; Body Weight; Bone and Bones; Ca | 1994 |
[Acetylsalicylic acid and pre-eclampsia/growth retardation (II)].
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy | 1994 |
Aspirin in pregnancy.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension; Parity; Pregnancy; Pregnancy Compli | 1993 |
Aspirin in pregnancy.
Topics: Aspirin; Bias; Female; Fetal Growth Retardation; Humans; Hypertension; Pregnancy; Pregnancy Complica | 1993 |
Aspirin in pregnancy.
Topics: Aspirin; Docosahexaenoic Acids; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Infant, P | 1993 |
Low-dose aspirin in pregnancy: changes in patterns of prescription in The Netherlands.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension; Netherlands; Pre-Eclampsia; Pregnan | 1993 |
Low dose aspirin in pregnancy: a clinical and biochemical study of effects on the newborn.
Topics: Aspirin; Birth Weight; Cerebral Hemorrhage; Female; Fetal Blood; Fetal Growth Retardation; Gestation | 1993 |
Changes in platelet reactivity following aspirin treatment for pre-eclampsia.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Longitudinal Studies; Platelet A | 1993 |
Lupus anticoagulant. Significance in habitual first-trimester abortion.
Topics: Abortion, Habitual; Adult; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Humans; Lupus Coa | 1993 |
Angiotensin sensitivity predicts aspirin benefit in placental insufficiency.
Topics: Angiotensins; Aspirin; Female; Fetal Growth Retardation; Humans; Placental Insufficiency; Pregnancy; | 1993 |
[Acetylsalicylic acid and pre-eclampsia/growth retardation].
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy | 1993 |
Uterine Doppler wave form and the prediction of the recurrence of pre-eclampsia and intra-uterine growth retardation in patients treated with low-dose aspirin.
Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Follow-Up Studie | 1995 |
[Dosage of acetylsalicylic acid in the prevention and therapy of intrauterine growth retardation].
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Pregnancy; Retrospective Studies | 1997 |
Preventing intrauterine growth retardation with aspirin: does it work?
Topics: Aspirin; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Female; Fetal Growth Retardation; Huma | 1998 |
Titration of antiplatelet treatment in pregnant women at risk of preeclampsia.
Topics: Abortion, Spontaneous; Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; | 1998 |
Low-dose aspirin not for pre-eclampsia.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Incidence; Placebos; Platelet Activation; Platele | 1998 |
Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study.
Topics: Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Gestational Age; Heparin, Low- | 1998 |
A novel approach to the management of pregnancies complicated by uteroplacental insufficiency and previous stillbirth.
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Fetal Death; Fetal Growth Retardation; Fetal Moni | 1998 |
Effect of aspirin in pregnant women is dependent on increase in bleeding time.
Topics: Adult; Antihypertensive Agents; Arteries; Aspirin; Bleeding Time; Cohort Studies; Dose-Response Rela | 1999 |
[Favorable outcome of a subdural hematoma diagnosed in utero].
Topics: Adult; Aspirin; Female; Fetal Growth Retardation; Follow-Up Studies; Hematoma, Subdural; Humans; Inf | 1999 |
Aspirin and prevention of vascular complications: there are still indications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Female; Fetal Growth Re | 2000 |
Administration of low-dose aspirin to mothers with small for gestational age fetuses and abnormal umbilical Doppler studies to increase birthweight: a randomised double-blind controlled trial.
Topics: Aspirin; Drug Administration Schedule; Embryonic and Fetal Development; Female; Fetal Growth Retarda | 2000 |
Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications.
Topics: Abortion, Habitual; Aspirin; Female; Fetal Growth Retardation; Fetus; Heparin, Low-Molecular-Weight; | 2001 |
Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Folic Acid; Gestational Age; HELLP Syndrome | 2001 |
Platelet life span in pregnancies resulting in small-for-gestational age infants.
Topics: Aspirin; Blood Platelets; Cell Survival; Female; Fetal Growth Retardation; Humans; Infant, Newborn; | 1979 |
Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin.
Topics: Abortion, Spontaneous; Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Enzym | 1992 |
Assessment of whole-blood spontaneous platelet aggregation during pregnancy using an impedance particle counter.
Topics: Adolescent; Adult; Aspirin; Electric Impedance; Female; Fetal Growth Retardation; Gestational Age; H | 1992 |
[A trial of low-dose aspirin therapy in high-risk pregnancy].
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Calcium; Female; Fetal Death; Fetal Growth Retardation; Human | 1992 |
The use of low dose aspirin in pregnancy.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy | 1992 |
Low-dose aspirin during pregnancy.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Pregnancy | 1991 |
[Aspirin and pregnancy].
Topics: Aspirin; Blood Coagulation Factors; Female; Fetal Death; Fetal Growth Retardation; Humans; Hypertens | 1990 |
[Effect of low-dose aspirin therapy on utero-placental blood flow and malondialdehyde (MDA) as an indicator of its therapeutic effect].
Topics: Adult; Aspirin; Epoprostenol; Female; Fetal Growth Retardation; Humans; Malondialdehyde; Middle Aged | 1990 |
Low-dose aspirin in pregnancy.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension; Infant, Newborn; Lupus Erythematosu | 1988 |
Prophylactic low-dose aspirin and dipyridamole in pregnancy.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Fetal Death; Fetal Growth Retardation; Hum | 1988 |
Essential thrombocythemia associated with recurrent abortions and fetal growth retardation.
Topics: Abortion, Habitual; Adult; Aspirin; Dipyridamole; Female; Fetal Growth Retardation; Humans; Platelet | 1987 |
Obstetric complications associated with the lupus anticoagulant.
Topics: Abortion, Spontaneous; Aspirin; Blood Coagulation Factors; Blood Coagulation Tests; Female; Fetal De | 1985 |